<!DOCTYPE html>
<html lang="zh-CN" data-theme="light">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width,initial-scale=1" />
    <meta name="generator" content="VuePress 2.0.0-beta.48" />
    <meta name="theme" content="VuePress Theme Hope" />
    <meta property="og:url" content="https://github.com/seasideccm/ssccm/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html"><meta property="og:site_name" content="æµ·æ»¨é‡ç—‡"><meta property="og:title" content="è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å’Œæ”¯æŒ"><meta property="og:type" content="article"><meta property="og:locale" content="zh-CN"><meta property="og:locale:alternate" content="en-US"><script src="https://kit.fontawesome.com/ca37c296c5.js" crossorigin="anonymous"></script><script src="https://cdn.staticfile.org/jquery/1.10.2/jquery.min.js"></script><title>è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å’Œæ”¯æŒ | æµ·æ»¨é‡ç—‡</title><meta name="description" content="é‡ç—‡å­¦ä¹ äº¤æµå¹³å°">
    <style>
      :root {
        --bg-color: #fff;
      }

      html[data-theme="dark"] {
        --bg-color: #1d2025;
      }

      html,
      body {
        background-color: var(--bg-color);
      }
    </style>
    <script>
      const userMode = localStorage.getItem("vuepress-theme-hope-scheme");
      const systemDarkMode =
        window.matchMedia &&
        window.matchMedia("(prefers-color-scheme: dark)").matches;

      if (userMode === "dark" || (userMode !== "light" && systemDarkMode)) {
        document.querySelector("html").setAttribute("data-theme", "dark");
      }
    </script>
    <link rel="stylesheet" href="/assets/style.c0ce0d3b.css">
    <link rel="modulepreload" href="/assets/app.c13ece5a.js"><link rel="modulepreload" href="/assets/Hemodynamic_Monitoring_and_Support.html.aaa1e108.js"><link rel="modulepreload" href="/assets/plugin-vue_export-helper.21dcd24c.js"><link rel="modulepreload" href="/assets/Hemodynamic_Monitoring_and_Support.html.d1d22e14.js">
  </head>
  <body>
    <div id="app"><!--[--><!--[--><!--[--><span tabindex="-1"></span><a href="#main-content" class="skip-link sr-only">Skip to content</a><!--]--><div class="theme-container has-toc"><!--[--><!--[--><header class="navbar auto-hide"><div class="navbar-left"><button class="toggle-sidebar-button" title="Toggle Sidebar"><span class="icon"></span></button><!----><a href="/" class="brand"><img class="logo" src="/logo.png" alt="æµ·æ»¨é‡ç—‡"><!----><span class="site-name hide-in-pad">æµ·æ»¨é‡ç—‡</span></a><!----></div><div class="navbar-center"><!----><nav class="nav-links"><div class="nav-item hide-in-mobile"><a href="/" class="nav-link" aria-label="SSCC"><!---->SSCC<!----></a></div><div class="nav-item hide-in-mobile"><a href="/blog.html" class="nav-link" aria-label="åšå®¢"><!---->åšå®¢<!----></a></div><div class="nav-item hide-in-mobile"><a href="/guidelines/" class="nav-link" aria-label="æŒ‡å—"><span class="icon fas fa-fa-light fa-compass" style=""></span>æŒ‡å—<!----></a></div><div class="nav-item hide-in-mobile"><a href="/bloodflow/" class="nav-link active" aria-label="è¡€æµ"><span class="icon fas fa-fa-thin fa-staff-aesculapius" style=""></span>è¡€æµ<!----></a></div><div class="nav-item hide-in-mobile"><a href="/slide/" class="nav-link" aria-label="è¯¾ä»¶"><span class="icon fas fa-fa-light fa-chalkboard" style=""></span>è¯¾ä»¶<!----></a></div></nav><!----></div><div class="navbar-right"><!----><div class="nav-item"><div class="dropdown-wrapper i18n-dropdown"><button class="dropdown-title" type="button" aria-label="é€‰æ‹©è¯­è¨€"><!--[--><svg xmlns="http://www.w3.org/2000/svg" class="icon i18n-icon" viewbox="0 0 1024 1024" fill="currentColor" aria-label="i18n icon" style="width:1rem;height:1rem;vertical-align:middle;"><path d="M379.392 460.8 494.08 575.488l-42.496 102.4L307.2 532.48 138.24 701.44l-71.68-72.704L234.496 460.8l-45.056-45.056c-27.136-27.136-51.2-66.56-66.56-108.544h112.64c7.68 14.336 16.896 27.136 26.112 35.84l45.568 46.08 45.056-45.056C382.976 312.32 409.6 247.808 409.6 204.8H0V102.4h256V0h102.4v102.4h256v102.4H512c0 70.144-37.888 161.28-87.04 210.944L378.88 460.8zM576 870.4 512 1024H409.6l256-614.4H768l256 614.4H921.6l-64-153.6H576zM618.496 768h196.608L716.8 532.48 618.496 768z"></path></svg><!--]--><span class="arrow"></span><ul class="nav-dropdown"><li class="dropdown-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html" class="router-link-active router-link-exact-active nav-link active" aria-label="ç®€ä½“ä¸­æ–‡"><!---->ç®€ä½“ä¸­æ–‡<!----></a></li><li class="dropdown-item"><a href="/en/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html" class="nav-link" aria-label="English"><!---->English<!----></a></li></ul></button></div></div><div class="nav-item"><a class="repo-link" href="https://github.com/seasideccm/ssccm" target="_blank" rel="noopener noreferrer" aria-label="GitHub"><svg xmlns="http://www.w3.org/2000/svg" class="icon github-icon" viewbox="0 0 1024 1024" fill="currentColor" aria-label="github icon" style="width:1.25rem;height:1.25rem;vertical-align:middle;"><path d="M511.957 21.333C241.024 21.333 21.333 240.981 21.333 512c0 216.832 140.544 400.725 335.574 465.664 24.49 4.395 32.256-10.07 32.256-23.083 0-11.69.256-44.245 0-85.205-136.448 29.61-164.736-64.64-164.736-64.64-22.315-56.704-54.4-71.765-54.4-71.765-44.587-30.464 3.285-29.824 3.285-29.824 49.195 3.413 75.179 50.517 75.179 50.517 43.776 75.008 114.816 53.333 142.762 40.79 4.523-31.66 17.152-53.377 31.19-65.537-108.971-12.458-223.488-54.485-223.488-242.602 0-53.547 19.114-97.323 50.517-131.67-5.035-12.33-21.93-62.293 4.779-129.834 0 0 41.258-13.184 134.912 50.346a469.803 469.803 0 0 1 122.88-16.554c41.642.213 83.626 5.632 122.88 16.554 93.653-63.488 134.784-50.346 134.784-50.346 26.752 67.541 9.898 117.504 4.864 129.834 31.402 34.347 50.474 78.123 50.474 131.67 0 188.586-114.73 230.016-224.042 242.09 17.578 15.232 33.578 44.672 33.578 90.454v135.85c0 13.142 7.936 27.606 32.854 22.87C862.25 912.597 1002.667 728.747 1002.667 512c0-271.019-219.648-490.667-490.71-490.667z"></path></svg></a></div><div class="nav-item hide-in-mobile"><button id="appearance-switch"><svg xmlns="http://www.w3.org/2000/svg" class="icon auto-icon" viewbox="0 0 1024 1024" fill="currentColor" aria-label="auto icon" style="display:block;"><path d="M512 992C246.92 992 32 777.08 32 512S246.92 32 512 32s480 214.92 480 480-214.92 480-480 480zm0-840c-198.78 0-360 161.22-360 360 0 198.84 161.22 360 360 360s360-161.16 360-360c0-198.78-161.22-360-360-360zm0 660V212c165.72 0 300 134.34 300 300 0 165.72-134.28 300-300 300z"></path></svg><svg xmlns="http://www.w3.org/2000/svg" class="icon dark-icon" viewbox="0 0 1024 1024" fill="currentColor" aria-label="dark icon" style="display:none;"><path d="M524.8 938.667h-4.267a439.893 439.893 0 0 1-313.173-134.4 446.293 446.293 0 0 1-11.093-597.334A432.213 432.213 0 0 1 366.933 90.027a42.667 42.667 0 0 1 45.227 9.386 42.667 42.667 0 0 1 10.24 42.667 358.4 358.4 0 0 0 82.773 375.893 361.387 361.387 0 0 0 376.747 82.774 42.667 42.667 0 0 1 54.187 55.04 433.493 433.493 0 0 1-99.84 154.88 438.613 438.613 0 0 1-311.467 128z"></path></svg><svg xmlns="http://www.w3.org/2000/svg" class="icon light-icon" viewbox="0 0 1024 1024" fill="currentColor" aria-label="light icon" style="display:none;"><path d="M952 552h-80a40 40 0 0 1 0-80h80a40 40 0 0 1 0 80zM801.88 280.08a41 41 0 0 1-57.96-57.96l57.96-58a41.04 41.04 0 0 1 58 58l-58 57.96zM512 752a240 240 0 1 1 0-480 240 240 0 0 1 0 480zm0-560a40 40 0 0 1-40-40V72a40 40 0 0 1 80 0v80a40 40 0 0 1-40 40zm-289.88 88.08-58-57.96a41.04 41.04 0 0 1 58-58l57.96 58a41 41 0 0 1-57.96 57.96zM192 512a40 40 0 0 1-40 40H72a40 40 0 0 1 0-80h80a40 40 0 0 1 40 40zm30.12 231.92a41 41 0 0 1 57.96 57.96l-57.96 58a41.04 41.04 0 0 1-58-58l58-57.96zM512 832a40 40 0 0 1 40 40v80a40 40 0 0 1-80 0v-80a40 40 0 0 1 40-40zm289.88-88.08 58 57.96a41.04 41.04 0 0 1-58 58l-57.96-58a41 41 0 0 1 57.96-57.96z"></path></svg></button></div><div class="search-box" role="search" data-v-361968cd><input value="" aria-label="Search" class="" placeholder="Search" autocomplete="off" spellcheck="false" data-v-361968cd><!----></div><!----><button class="toggle-navbar-button" aria-label="Toggle Navbar" aria-expanded="false" aria-controls="nav-screen"><span class="button-container"><span class="button-top"></span><span class="button-middle"></span><span class="button-bottom"></span></span></button></div></header><!----><!--]--><!----><div class="toggle-sidebar-wrapper"><span class="arrow left"></span></div><aside class="sidebar"><!--[--><!----><!--]--><ul class="sidebar-links"><li><!--[--><a href="/" class="nav-link sidebar-link sidebar-page" aria-label="SSCC"><!---->SSCC<!----></a><ul class="sidebar-sub-headers"></ul><!--]--></li><li><!--[--><section class="sidebar-group"><button class="sidebar-heading clickable"><!----><span class="title">è¯¾ä»¶</span><span class="arrow right"></span></button><!----></section><!--]--></li><li><!--[--><section class="sidebar-group"><button class="sidebar-heading clickable active"><!----><span class="title">è¡€æµç†è®ºå’ŒæŠ€æœ¯</span><span class="arrow down"></span></button><ul class="sidebar-links"><li><!--[--><section class="sidebar-group"><button class="sidebar-heading clickable"><!----><span class="title">è„‘è¡€æµ</span><span class="arrow right"></span></button><!----></section><!--]--></li><li><!--[--><a href="/bloodflow/Microstructure_and_cerebral_blood_flow_changes_in_patients_recovered_from_COVID_19.html" class="nav-link sidebar-link sidebar-page" aria-label="æ— ç¥ç»ç³»ç»Ÿè¡¨ç°çš„ COVID-19 åº·å¤æ‚£è€…å¤§è„‘å¾®ç»“æ„å’Œè„‘è¡€æµçš„é•¿æœŸåæœ"><!---->æ— ç¥ç»ç³»ç»Ÿè¡¨ç°çš„ COVID-19 åº·å¤æ‚£è€…å¤§è„‘å¾®ç»“æ„å’Œè„‘è¡€æµçš„é•¿æœŸåæœ<!----></a><ul class="sidebar-sub-headers"></ul><!--]--></li><li><!--[--><a href="/bloodflow/Regional_perfusion_monitoring_in_shock.html" class="nav-link sidebar-link sidebar-page" aria-label="ä¼‘å…‹å±€éƒ¨çŒæ³¨ç›‘æµ‹"><!---->ä¼‘å…‹å±€éƒ¨çŒæ³¨ç›‘æµ‹<!----></a><ul class="sidebar-sub-headers"></ul><!--]--></li><li><!--[--><a href="/bloodflow/blood_flow.html" class="nav-link sidebar-link sidebar-page" aria-label="è¡€æµ"><!---->è¡€æµ<!----></a><ul class="sidebar-sub-headers"></ul><!--]--></li><li><!--[--><section class="sidebar-group"><button class="sidebar-heading clickable active"><!----><span class="title">è¡€æµæŠ€æœ¯</span><span class="arrow down"></span></button><ul class="sidebar-links"><li><!--[--><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html" class="router-link-active router-link-exact-active nav-link active sidebar-link sidebar-page active" aria-label="è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å’Œæ”¯æŒ"><!---->è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å’Œæ”¯æŒ<!----></a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#some-key-steps-in-the-history-of-hemodynamic-monitoring-è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å²ä¸Šçš„ä¸€äº›å…³é”®è½¬å˜" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="SOME KEY STEPS IN THE HISTORY OF HEMODYNAMIC MONITORING è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å²ä¸Šçš„ä¸€äº›å…³é”®è½¬å˜"><!---->SOME KEY STEPS IN THE HISTORY OF HEMODYNAMIC MONITORING è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å²ä¸Šçš„ä¸€äº›å…³é”®è½¬å˜<!----></a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#from-pressures-to-blood-flow-ä»è¡€å‹åˆ°è¡€æµ" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="From Pressures to Blood Flow ä»è¡€å‹åˆ°è¡€æµ"><!---->From Pressures to Blood Flow ä»è¡€å‹åˆ°è¡€æµ<!----></a><ul class="sidebar-sub-headers"></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-importance-of-cardiac-output-å¿ƒè¾“å‡ºé‡çš„é‡è¦æ€§" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="The Importance of Cardiac Output å¿ƒè¾“å‡ºé‡çš„é‡è¦æ€§"><!---->The Importance of Cardiac Output å¿ƒè¾“å‡ºé‡çš„é‡è¦æ€§<!----></a><ul class="sidebar-sub-headers"></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-concept-of-oxygen-delivery-oxygen-consumption-relationships-and-the-importance-of-svo2-æ°§ä¾›-æ°§è€—å…³ç³»çš„æ¦‚å¿µå’Œ-svo2-çš„é‡è¦æ€§" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="The Concept of Oxygen Delivery/Oxygen Consumption Relationships and the Importance of Svo2 æ°§ä¾›/æ°§è€—å…³ç³»çš„æ¦‚å¿µå’Œ Svo2 çš„é‡è¦æ€§"><!---->The Concept of Oxygen Delivery/Oxygen Consumption Relationships and the Importance of Svo2 æ°§ä¾›/æ°§è€—å…³ç³»çš„æ¦‚å¿µå’Œ Svo2 çš„é‡è¦æ€§<!----></a><ul class="sidebar-sub-headers"></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#blood-lactate-concentrations-è¡€ä¹³é…¸æµ“åº¦" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="Blood Lactate Concentrations è¡€ä¹³é…¸æµ“åº¦"><!---->Blood Lactate Concentrations è¡€ä¹³é…¸æµ“åº¦<!----></a><ul class="sidebar-sub-headers"></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-importance-of-peripheral-perfusion-å¤–å‘¨çŒæ³¨çš„é‡è¦æ€§" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="The Importance of Peripheral Perfusion å¤–å‘¨çŒæ³¨çš„é‡è¦æ€§"><!---->The Importance of Peripheral Perfusion å¤–å‘¨çŒæ³¨çš„é‡è¦æ€§<!----></a><ul class="sidebar-sub-headers"></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-importance-of-the-microcirculation-å¾®å¾ªç¯çš„é‡è¦æ€§" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="The Importance of the Microcirculation å¾®å¾ªç¯çš„é‡è¦æ€§"><!---->The Importance of the Microcirculation å¾®å¾ªç¯çš„é‡è¦æ€§<!----></a><ul class="sidebar-sub-headers"></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-move-toward-less-invasive-techniques-æœç€å¾®åˆ›æŠ€æœ¯å‘å±•" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="The Move Toward Less Invasive Techniques æœç€å¾®åˆ›æŠ€æœ¯å‘å±•"><!---->The Move Toward Less Invasive Techniques æœç€å¾®åˆ›æŠ€æœ¯å‘å±•<!----></a><ul class="sidebar-sub-headers"></ul></li></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#hemodynamic-monitoring-during-administration-of-key-therapeutic-interventions-in-shock-ä¼‘å…‹è¿›è¡Œå…³é”®æ²»ç–—å¹²é¢„æ—¶çš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="HEMODYNAMIC MONITORING DURING ADMINISTRATION OF KEY THERAPEUTIC INTERVENTIONS IN SHOCK ä¼‘å…‹è¿›è¡Œå…³é”®æ²»ç–—å¹²é¢„æ—¶çš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹"><!---->HEMODYNAMIC MONITORING DURING ADMINISTRATION OF KEY THERAPEUTIC INTERVENTIONS IN SHOCK ä¼‘å…‹è¿›è¡Œå…³é”®æ²»ç–—å¹²é¢„æ—¶çš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹<!----></a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#ventilate-é€šæ°”" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="Ventilate é€šæ°”"><!---->Ventilate é€šæ°”<!----></a><ul class="sidebar-sub-headers"></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#infuse-è¾“æ¶²" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="Infuse è¾“æ¶²"><!---->Infuse è¾“æ¶²<!----></a><ul class="sidebar-sub-headers"></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#type-of-fluid-and-blood-transfusions-è¾“æ¶²å’Œè¾“è¡€çš„ç§ç±»ã€‚" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="Type of Fluid and Blood Transfusions.è¾“æ¶²å’Œè¾“è¡€çš„ç§ç±»ã€‚"><!---->Type of Fluid and Blood Transfusions.è¾“æ¶²å’Œè¾“è¡€çš„ç§ç±»ã€‚<!----></a><ul class="sidebar-sub-headers"></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#pump-æ³µ" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="Pump æ³µ"><!---->Pump æ³µ<!----></a><ul class="sidebar-sub-headers"></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-future-of-hemodynamic-monitoring-è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹çš„æœªæ¥" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="The Future of Hemodynamic Monitoring è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹çš„æœªæ¥"><!---->The Future of Hemodynamic Monitoring è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹çš„æœªæ¥<!----></a><ul class="sidebar-sub-headers"></ul></li></ul></li><li class="sidebar-sub-header"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#conclusions-ç»“è®º" class="router-link-active router-link-exact-active nav-link sidebar-link heading" aria-label="CONCLUSIONS ç»“è®º"><!---->CONCLUSIONS ç»“è®º<!----></a><ul class="sidebar-sub-headers"></ul></li></ul><!--]--></li></ul></section><!--]--></li></ul></section><!--]--></li><li><!--[--><section class="sidebar-group"><button class="sidebar-heading clickable"><!----><span class="title">æŒ‡å—ç›®å½•</span><span class="arrow right"></span></button><!----></section><!--]--></li><li><!--[--><section class="sidebar-group"><button class="sidebar-heading clickable"><!----><span class="title">é‡ç—‡åŒ»å­¦æ–°è§†ç‚¹</span><span class="arrow right"></span></button><!----></section><!--]--></li></ul><!--[--><!----><!--]--></aside><!--[--><main class="page" id="main-content"><!--[--><!----><nav class="breadcrumb disable"></nav><div class="page-title"><h1><!---->è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å’Œæ”¯æŒ</h1><div class="page-info"><span class="author-info" aria-label="ä½œè€…ğŸ–Š" data-balloon-pos="down" isoriginal="false" pageview="false"><svg xmlns="http://www.w3.org/2000/svg" class="icon author-icon" viewbox="0 0 1024 1024" fill="currentColor" aria-label="author icon"><path d="M649.6 633.6c86.4-48 147.2-144 147.2-249.6 0-160-128-288-288-288s-288 128-288 288c0 108.8 57.6 201.6 147.2 249.6-121.6 48-214.4 153.6-240 288-3.2 9.6 0 19.2 6.4 25.6 3.2 9.6 12.8 12.8 22.4 12.8h704c9.6 0 19.2-3.2 25.6-12.8 6.4-6.4 9.6-16 6.4-25.6-25.6-134.4-121.6-240-243.2-288z"></path></svg><span><a class="author-item" href="https://github.com/seasideccm/ssccm" target="_blank" rel="noopener noreferrer">SSCC</a></span><span property="author" content="SSCC"></span></span><!----><!----><!----><!----><span class="reading-time-info" aria-label="é˜…è¯»æ—¶é—´âŒ›" data-balloon-pos="down" isoriginal="false" pageview="false"><svg xmlns="http://www.w3.org/2000/svg" class="icon timer-icon" viewbox="0 0 1024 1024" fill="currentColor" aria-label="timer icon"><path d="M799.387 122.15c4.402-2.978 7.38-7.897 7.38-13.463v-1.165c0-8.933-7.38-16.312-16.312-16.312H256.33c-8.933 0-16.311 7.38-16.311 16.312v1.165c0 5.825 2.977 10.874 7.637 13.592 4.143 194.44 97.22 354.963 220.201 392.763-122.204 37.542-214.893 196.511-220.2 389.397-4.661 5.049-7.638 11.651-7.638 19.03v5.825h566.49v-5.825c0-7.379-2.849-13.981-7.509-18.9-5.049-193.016-97.867-351.985-220.2-389.527 123.24-37.67 216.446-198.453 220.588-392.892zM531.16 450.445v352.632c117.674 1.553 211.787 40.778 211.787 88.676H304.097c0-48.286 95.149-87.382 213.728-88.676V450.445c-93.077-3.107-167.901-81.297-167.901-177.093 0-8.803 6.99-15.793 15.793-15.793 8.803 0 15.794 6.99 15.794 15.793 0 80.261 63.69 145.635 142.01 145.635s142.011-65.374 142.011-145.635c0-8.803 6.99-15.793 15.794-15.793s15.793 6.99 15.793 15.793c0 95.019-73.789 172.82-165.96 177.093z"></path></svg><span>å¤§çº¦ 59 åˆ†é’Ÿ</span><meta property="timeRequired" content="PT59M"></span></div><hr></div><div class="toc-place-holder"><aside id="toc"><div class="toc-header">æ­¤é¡µå†…å®¹</div><div class="toc-wrapper"><ul class="toc-list"><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#some-key-steps-in-the-history-of-hemodynamic-monitoring-è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å²ä¸Šçš„ä¸€äº›å…³é”®è½¬å˜" class="router-link-active router-link-exact-active toc-link level2">SOME KEY STEPS IN THE HISTORY OF HEMODYNAMIC MONITORING è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å²ä¸Šçš„ä¸€äº›å…³é”®è½¬å˜</a></li><ul class="toc-list"><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#from-pressures-to-blood-flow-ä»è¡€å‹åˆ°è¡€æµ" class="router-link-active router-link-exact-active toc-link level3">From Pressures to Blood Flow ä»è¡€å‹åˆ°è¡€æµ</a></li><!----><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-importance-of-cardiac-output-å¿ƒè¾“å‡ºé‡çš„é‡è¦æ€§" class="router-link-active router-link-exact-active toc-link level3">The Importance of Cardiac Output å¿ƒè¾“å‡ºé‡çš„é‡è¦æ€§</a></li><!----><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-concept-of-oxygen-delivery-oxygen-consumption-relationships-and-the-importance-of-svo2-æ°§ä¾›-æ°§è€—å…³ç³»çš„æ¦‚å¿µå’Œ-svo2-çš„é‡è¦æ€§" class="router-link-active router-link-exact-active toc-link level3">The Concept of Oxygen Delivery/Oxygen Consumption Relationships and the Importance of Svo2 æ°§ä¾›/æ°§è€—å…³ç³»çš„æ¦‚å¿µå’Œ Svo2 çš„é‡è¦æ€§</a></li><!----><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#blood-lactate-concentrations-è¡€ä¹³é…¸æµ“åº¦" class="router-link-active router-link-exact-active toc-link level3">Blood Lactate Concentrations è¡€ä¹³é…¸æµ“åº¦</a></li><!----><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-importance-of-peripheral-perfusion-å¤–å‘¨çŒæ³¨çš„é‡è¦æ€§" class="router-link-active router-link-exact-active toc-link level3">The Importance of Peripheral Perfusion å¤–å‘¨çŒæ³¨çš„é‡è¦æ€§</a></li><!----><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-importance-of-the-microcirculation-å¾®å¾ªç¯çš„é‡è¦æ€§" class="router-link-active router-link-exact-active toc-link level3">The Importance of the Microcirculation å¾®å¾ªç¯çš„é‡è¦æ€§</a></li><!----><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-move-toward-less-invasive-techniques-æœç€å¾®åˆ›æŠ€æœ¯å‘å±•" class="router-link-active router-link-exact-active toc-link level3">The Move Toward Less Invasive Techniques æœç€å¾®åˆ›æŠ€æœ¯å‘å±•</a></li><!----><!--]--></ul><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#hemodynamic-monitoring-during-administration-of-key-therapeutic-interventions-in-shock-ä¼‘å…‹è¿›è¡Œå…³é”®æ²»ç–—å¹²é¢„æ—¶çš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹" class="router-link-active router-link-exact-active toc-link level2">HEMODYNAMIC MONITORING DURING ADMINISTRATION OF KEY THERAPEUTIC INTERVENTIONS IN SHOCK ä¼‘å…‹è¿›è¡Œå…³é”®æ²»ç–—å¹²é¢„æ—¶çš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹</a></li><ul class="toc-list"><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#ventilate-é€šæ°”" class="router-link-active router-link-exact-active toc-link level3">Ventilate é€šæ°”</a></li><!----><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#infuse-è¾“æ¶²" class="router-link-active router-link-exact-active toc-link level3">Infuse è¾“æ¶²</a></li><!----><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#type-of-fluid-and-blood-transfusions-è¾“æ¶²å’Œè¾“è¡€çš„ç§ç±»ã€‚" class="router-link-active router-link-exact-active toc-link level3">Type of Fluid and Blood Transfusions.è¾“æ¶²å’Œè¾“è¡€çš„ç§ç±»ã€‚</a></li><!----><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#pump-æ³µ" class="router-link-active router-link-exact-active toc-link level3">Pump æ³µ</a></li><!----><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#the-future-of-hemodynamic-monitoring-è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹çš„æœªæ¥" class="router-link-active router-link-exact-active toc-link level3">The Future of Hemodynamic Monitoring è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹çš„æœªæ¥</a></li><!----><!--]--></ul><!--]--><!--[--><li class="toc-item"><a aria-current="page" href="/bloodflow/techniques%20of%20blood%20flow/Hemodynamic_Monitoring_and_Support.html#conclusions-ç»“è®º" class="router-link-active router-link-exact-active toc-link level2">CONCLUSIONS ç»“è®º</a></li><!----><!--]--></ul></div></aside></div><!----><div class="theme-hope-content"><h1 id="è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å’Œæ”¯æŒ" tabindex="-1"><a class="header-anchor" href="#è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å’Œæ”¯æŒ" aria-hidden="true">#</a> è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å’Œæ”¯æŒ</h1><p>Vincent Jean-Louis MD PhD FCCM; Joosten, Alexandre MD, PhD; Saugel, Bernd MDVincent Jean-Louis MD åšå£« FCCM; Joosten, Alexandre MD, PhD; Saugel, Bernd MD</p><p>Critical Care Medicine. 49: p 1638-1650, October 2021. é‡ç—‡åŒ»å­¦.49: p 1638-1650, October 2021.</p><p>doi: 10.1097/CCM.0000000000005213 doi: 10.1097/CCM.0000000000005213</p><p>Author Information ä½œè€…ä¿¡æ¯</p><p>1 Department of Intensive Care, Erasme Hospital, UniversitÃ© libre de Bruxelles, Brussels, Belgium. 1 æ¯”åˆ©æ—¶å¸ƒé²å¡å°”è‡ªç”±å¤§å­¦ Erasme åŒ»é™¢é‡ç—‡ç›‘æŠ¤éƒ¨ã€‚</p><p>2 Department of Anesthesiology, Erasme Hospital, UniversitÃ© Libre de Bruxelles, Brussels, Belgium. 2 æ¯”åˆ©æ—¶å¸ƒé²å¡å°”è‡ªç”±å¤§å­¦ Erasme åŒ»é™¢éº»é†‰å­¦ç³»ã€‚</p><p>3 Department of Anesthesiology and Intensive Care, HÃ´pitaux Universitaires Paris-Sud, UniversitÃ© Paris-Sud, UniversitÃ© Paris-Saclay, Paul Brousse Hospital, Assistance Publique HÃ´pitaux de Paris (APHP), Villejuif, France. 3 éº»é†‰å­¦å’Œé‡ç—‡ç›‘æŠ¤ç³»ï¼Œå·´é»å—å¤§å­¦ï¼Œå·´é»å—å¤§å­¦ï¼Œå·´é»-è¨å…‹é›·å¤§å­¦ï¼Œä¿ç½—-å¸ƒé²æ–¯åŒ»é™¢ï¼Œå·´é»å…¬å…±æ´åŠ©åŒ»é™¢ï¼ˆAPHPï¼‰ï¼Œæ³•å›½ç»´å‹’å°¤å¤«ã€‚</p><p>4 Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4 å¾·å›½æ±‰å ¡ï¼Œæ±‰å ¡å¤§å­¦åŒ»å­¦ä¸­å¿ƒéº»é†‰å­¦å’Œé‡ç—‡ç›‘æŠ¤åŒ»å­¦ä¸­å¿ƒéº»é†‰å­¦ç³»ã€‚</p><p>Dr. Vincent drafted the article. Drs. Joosten and Saugel revised it for critical content. All authors read and approved the final version. æ–‡æ£®ç‰¹åšå£«èµ·è‰äº†è¿™ç¯‡æ–‡ç« ã€‚Joosten å’Œ Saugel åšå£«ä¿®æ”¹äº†æ–‡ç« çš„å…³é”®å†…å®¹ã€‚æ‰€æœ‰ä½œè€…éƒ½é˜…è¯»å¹¶æ‰¹å‡†äº†æœ€ç»ˆç‰ˆæœ¬ã€‚</p><p>Dr. Joostenâ€™s institution received funding from Edwards Lifesciences. Dr. Saugel received funding from Edwards Lifesciences, Pulsion Medical Systems SE, CNSystems Medizintechnik GmbH, Retia Medical LLC, Philips Medizin Systeme BÃ¶blingen GmbH, and Tensys Medical. Dr. Vincent has disclosed that he does not have any potential conflicts of interest. Joosten åšå£«æ‰€åœ¨çš„æœºæ„æ¥å—äº† Edwards Lifesciences å…¬å¸çš„èµ„åŠ©ã€‚Saugel åšå£«ä» Edwards Lifesciencesã€Pulsion Medical Systems SEã€CNSystems Medizintechnik GmbHã€Retia Medical LLCã€Philips Medizin Systeme BÃ¶blingen GmbH å’Œ Tensys Medical è·å¾—èµ„åŠ©ã€‚æ–‡æ£®ç‰¹åšå£«é€éœ²ï¼Œä»–æ²¡æœ‰ä»»ä½•æ½œåœ¨çš„åˆ©ç›Šå†²çªã€‚</p><p>For information regarding this article, E-mail: [jlvincent@intensive.org](mailto: <a href="mailto:jlvincent@intensive.org">jlvincent@intensive.org</a>) æœ‰å…³æœ¬æ–‡çš„ä¿¡æ¯ï¼Œè¯·å‘ç”µå­é‚®ä»¶ï¼šjlvincent@intensive.org</p><p>Critically ill patients are carefully and closely monitored to assess the nature and severity of their disease process and to assess the need for and impact of different therapies. All organs can be monitored, some more easily than others, with hemodynamic monitoring of the cardiovascular system being the most frequent. Hemodynamic monitoring techniques have progressed immensely since the very early days of intensive care and perhaps particularly over the past 50 years, moving from the very earliest, bulky sphygmographs to measure arterial pressure, to invasive catheters to assess cardiac output, to the more recent development of noninvasive, digital monitors providing continuous values of multiple hemodynamic variables. Concepts have also changed as we move from global macrohemodynamic monitoring toward a more regional, microcirculatory perfusion approach and from maximal monitoring for all, to a much more individualized approach. Here, we will briefly review these changes.</p><p>å¯¹å±é‡ç—…äººè¿›è¡Œä¸¥å¯†çš„ç›‘æµ‹ï¼Œä»¥è¯„ä¼°å…¶ç–¾ç—…è¿‡ç¨‹çš„æ€§è´¨å’Œä¸¥é‡ç¨‹åº¦ï¼Œå¹¶è¯„ä¼°éœ€è¦å“ªäº›æ²»ç–—æ–¹æ³•å’Œç–—æ•ˆã€‚æ‰€æœ‰å™¨å®˜éƒ½å¯ç›‘æµ‹ï¼Œæœ‰çš„æ¯”å…¶ä»–å™¨å®˜æ›´å®¹æ˜“ç›‘æµ‹ï¼Œå…¶ä¸­å¿ƒè¡€ç®¡ç³»ç»Ÿçš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹æ˜¯æœ€å¸¸è§çš„ã€‚è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹æŠ€æœ¯ä»æœ‰é‡ç—‡ç›‘æŠ¤å¼€å§‹å°±æœ‰äº†å·¨å¤§çš„è¿›æ­¥ï¼Œä¹Ÿè®¸åœ¨è¿‡å»çš„ 50 å¹´é‡Œæ›´æ˜¯å¦‚æ­¤ï¼Œä»æœ€æ—©çš„æµ‹é‡åŠ¨è„‰å‹çš„ç¬¨é‡è¡€å‹è®¡ï¼Œåˆ°è¯„ä¼°å¿ƒè¾“å‡ºé‡çš„æœ‰åˆ›å¯¼ç®¡ï¼Œå†åˆ°æœ€è¿‘å¼€å‘çš„çš„è¿ç»­ç›‘æµ‹å¤šç§è¡€æµåŠ¨åŠ›å­¦å‚æ•°çš„æ— åˆ›æ•°å­—ç›‘æµ‹ä»ªã€‚éšç€æˆ‘ä»¬ä»å…¨èº«å®è§‚è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹è½¬å‘æ›´å¤šé‡‡ç”¨å±€éƒ¨è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹ã€å¾®å¾ªç¯çŒæ³¨è¯„ä¼°ï¼Œä»¥åŠä»å¯¹æ‰€æœ‰äººç›‘æµ‹æœ€å¤§åŒ–è½¬å‘è¯„ä¼°æ›´åŠ ä¸ªä½“åŒ–ï¼Œè§‚å¿µä¹Ÿéšä¹‹è½¬å˜ã€‚æ­¤æ—¶ï¼Œå°±è¿™äº›å˜åŒ–è¿›è¡Œç®€è¦å›é¡¾ã€‚</p><h2 id="some-key-steps-in-the-history-of-hemodynamic-monitoring-è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å²ä¸Šçš„ä¸€äº›å…³é”®è½¬å˜" tabindex="-1"><a class="header-anchor" href="#some-key-steps-in-the-history-of-hemodynamic-monitoring-è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å²ä¸Šçš„ä¸€äº›å…³é”®è½¬å˜" aria-hidden="true">#</a> SOME KEY STEPS IN THE HISTORY OF HEMODYNAMIC MONITORING è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å²ä¸Šçš„ä¸€äº›å…³é”®è½¬å˜</h2><h3 id="from-pressures-to-blood-flow-ä»è¡€å‹åˆ°è¡€æµ" tabindex="-1"><a class="header-anchor" href="#from-pressures-to-blood-flow-ä»è¡€å‹åˆ°è¡€æµ" aria-hidden="true">#</a> From Pressures to Blood Flow ä»è¡€å‹åˆ°è¡€æµ</h3><p>Monitoring of a patientâ€™s hemodynamic status initially concentrated on measuring arterial pressure. The fundamental hemodynamic principle that pressure is determined by flow and vascular tone (or vascular resistance) soon became evident and had a major impact on the development of hemodynamic monitoring. As technology advanced, the ability to perform more advanced hemodynamic assessment enabled better description and characterization of the different types of shock (hypovolemic, cardiogenic, distributive, and obstructive) as proposed by Weil and Henning in 1979 (<a href="#R1">1</a> , <a href="#R2">2</a> ). A clear separation was identified between shock with high systemic vascular resistance (SVR) (hypovolemic, cardiogenic, obstructive) and shock with low SVR (distributive), but it became apparent that the vascular resistance concept had major limitations. First, physiologically the line on a graph representing the relationship between intravascular pressure (on the <em>y</em>-axis) and flow (on the <em>x</em>-axis) does not start from the origin, as pressure is still positive in the absence of flow. Second, vasopressor therapy targeting an increase in SVR may result in an increase in arterial pressure but also a reduction in blood flow. Third, septic shock is not always associated with low SVR. These observations were the basis for the historical separation of septic shock into â€œcoldâ€ and â€œwarmâ€ types, possibly related to different types of organismâ€”Gram+ve and Gram-veâ€”in particular ( <a href="#R3">3</a> ), but, although still sometimes used in pediatric shock, these distinctions are not reliable. Patients with circulatory shock often present with a combination of several different types of shock; for example, in septic shock, cardiac output can be limited by hypovolemia and/or sepsis-related myocardial depression. In patients with acute respiratory failure, the effects of high airway pressures on right ventricular function can further complicate the hemodynamic pattern ( <a href="#R4">4</a> ). Hence, the concept of characterizing shock according to vascular resistance lost popularity, and we have rather stayed focused on the primary variables of pressures and cardiac output.</p><p>å¯¹ç—…äººè¡€æµåŠ¨åŠ›å­¦çŠ¶æ€çš„ç›‘æµ‹æœ€åˆé›†ä¸­äºæµ‹é‡åŠ¨è„‰å‹ã€‚è¡€æµå’Œè¡€ç®¡å¼ åŠ›ï¼ˆæˆ–è¡€ç®¡é˜»åŠ›ï¼‰å†³å®šå‹åŠ›çš„åŸºæœ¬è¡€æµåŠ¨åŠ›å­¦åŸç†å¾ˆå¿«è¢«è¯å®ï¼Œå¹¶å¯¹è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹çš„å‘å±•äº§ç”Ÿäº†é‡å¤§å½±å“ã€‚éšç€æŠ€æœ¯çš„è¿›æ­¥ï¼Œå…·æœ‰äº†é«˜çº§è¡€æµåŠ¨åŠ›å­¦è¯„ä¼°èƒ½åŠ›ï¼Œèƒ½å¤Ÿæ›´å¥½çš„æè¿°å’Œç•Œå®šï¼ˆ1ï¼Œ2ï¼‰ä¸åŒç±»å‹çš„ä¼‘å…‹ï¼ˆä½è¡€å®¹é‡ã€å¿ƒæºæ€§ã€åˆ†å¸ƒæ€§å’Œé˜»å¡æ€§ï¼‰ï¼Œæ­£å¦‚Weil å’Œ Henning åœ¨ 1979 å¹´æ‰€æå‡ºçš„ã€‚é«˜å¤–å‘¨è¡€ç®¡é˜»åŠ›ï¼ˆSVRï¼‰ï¼ˆä½è¡€å®¹é‡ã€å¿ƒæºæ€§ã€é˜»å¡æ€§ï¼‰å’Œä½ SVR ä¼‘å…‹ï¼ˆåˆ†å¸ƒæ€§ï¼‰è¢«æ˜ç¡®åˆ’åˆ†ï¼Œä½†æ˜¾ç„¶è¡€ç®¡é˜»åŠ›çš„æ¦‚å¿µå­˜åœ¨å¾ˆå¤§çš„å±€é™æ€§ã€‚é¦–å…ˆï¼Œåœ¨ç”Ÿç†ä¸Šï¼Œä»£è¡¨è¡€ç®¡å†…å‹åŠ›ï¼ˆY è½´ï¼‰å’Œè¡€æµï¼ˆX è½´ï¼‰ä¹‹é—´å…³ç³»çš„ç¤ºæ„å›¾ä¸Šçš„çº¿æ¡å¹¶ä¸æ˜¯ä»åŸç‚¹å¼€å§‹çš„ï¼Œè¿™æ˜¯å› ä¸ºåœ¨æ²¡æœ‰è¡€æµçš„æƒ…å†µä¸‹ï¼Œå‹åŠ›ä»ç„¶å¯ä»¥æ˜¯æ­£çš„ã€‚ç¬¬äºŒï¼Œä»¥å¢åŠ  SVR ä¸ºç›®æ ‡çš„ç¼©è¡€ç®¡æ²»ç–—å¯èƒ½ä¼šå¯¼è‡´åŠ¨è„‰å‹å‡é«˜ï¼Œä½†ä¹Ÿä¼šå¯¼è‡´è¡€æµå‡å°‘ã€‚ç¬¬ä¸‰ï¼Œè„“æ¯’ç—‡ä¼‘å…‹çš„ SVR å¹¶ä¸æ€»æ˜¯ä½çš„ã€‚è¿™äº›è§‚å¯Ÿç»“æœåœ¨å†å²ä¸Šæ˜¯å°†è„“æ¯’ç—‡ä¼‘å…‹åˆ†ä¸º &quot;å†· &quot;å’Œ &quot;æš– &quot;ä¸¤ç§ç±»å‹çš„ä¾æ®ï¼Œå°¤å…¶æ˜¯å¯èƒ½ä¸é©å…°æŸ“è‰²é˜³æ€§å’Œé˜´æ€§å¾®ç”Ÿç‰©çš„ä¸åŒç±»å‹æœ‰å…³ï¼ˆ3ï¼‰ï¼Œå°½ç®¡æœ‰æ—¶ä¹Ÿç”¨äºåŒºåˆ†å°å„¿ä¼‘å…‹ï¼Œä½†æ˜¯è¿™äº›å·®åˆ«å¹¶ä¸å¯é ã€‚å¾ªç¯ä¼‘å…‹æ‚£è€…å¸¸å¸¸è¡¨ç°ä¸ºå‡ ç§ä¸åŒç±»å‹çš„ä¼‘å…‹å…±å­˜ï¼›ä¾‹å¦‚ï¼Œåœ¨è„“æ¯’ç—‡ä¼‘å…‹ï¼Œå¿ƒè¾“å‡ºé‡å¯èƒ½å› ä½è¡€å®¹é‡å’Œ/æˆ–è„“æ¯’ç—‡å¿ƒè‚ŒæŠ‘åˆ¶è€Œä¸‹é™ã€‚åœ¨æ€¥æ€§å‘¼å¸è¡°ç«­æ‚£è€…ä¸­ï¼Œé«˜æ°”é“å‹åŠ›å¯¹å³å¿ƒå®¤åŠŸèƒ½çš„å½±å“å¯ä½¿è¡€æµåŠ¨åŠ›å­¦æ¨¡å¼è¿›ä¸€æ­¥å¤æ‚åŒ–ï¼ˆ4ï¼‰ã€‚å› æ­¤ï¼Œæ ¹æ®è¡€ç®¡é˜»åŠ›æ¥æè¿°ä¼‘å…‹çš„æ¦‚å¿µå·²ç»ä¸æµè¡Œäº†ï¼Œäººä»¬æ›´å…³æ³¨å‹åŠ›å’Œå¿ƒè¾“å‡ºé‡è¿™ä¸¤ä¸ªç›´æ¥å‚æ•°ã€‚</p><h3 id="the-importance-of-cardiac-output-å¿ƒè¾“å‡ºé‡çš„é‡è¦æ€§" tabindex="-1"><a class="header-anchor" href="#the-importance-of-cardiac-output-å¿ƒè¾“å‡ºé‡çš„é‡è¦æ€§" aria-hidden="true">#</a> The Importance of Cardiac Output å¿ƒè¾“å‡ºé‡çš„é‡è¦æ€§</h3><p>The first measurements of cardiac output, using indicator dilution techniques, were complicated and cumbersome ( <a href="#R5">5</a> ) but helped us recognize the large variability in cardiac output that can exist in patients. The development of the balloon-tipped pulmonary artery catheter (PAC) by Swan et al ( <a href="#R6">6</a> ) in 1970, just before the Society for Critical Care Medicine was founded in 1971, revolutionized our approach to the monitoring of cardiac output enabling the simpler pulmonary artery thermodilution technique ( <a href="#R7">7</a> ). The PAC had the additional benefit of enabling multiple hemodynamic variables (pulmonary artery pressures, pulmonary artery occlusion pressure [PAOP], SVR and pulmonary vascular resistance, core body temperature, mixed venous oxygen saturation [Svo<sub>2</sub>]) to be measured and monitored simultaneously. æœ€æ—©é‡‡ç”¨<strong>æŒ‡ç¤ºå‰‚ç¨€é‡ŠæŠ€æœ¯</strong>çš„å¿ƒè¾“å‡ºé‡æµ‹é‡è®¾å¤‡å³å¤æ‚åˆç¬¨é‡ï¼ˆ5ï¼‰ï¼Œä½†å¸®åŠ©æˆ‘ä»¬è®¤è¯†åˆ°ç—…äººçš„å¿ƒè¾“å‡ºé‡å¯ä»¥å­˜åœ¨å¾ˆå¤§çš„å˜å¼‚æ€§ã€‚1970 å¹´ï¼Œåœ¨ 1971 å¹´é‡ç—‡åŒ»å­¦ä¼šæˆç«‹å‰ï¼ŒSwan ç­‰äººï¼ˆ6ï¼‰å‘æ˜äº†å°–ç«¯å¸¦çƒå›Šçš„è‚ºåŠ¨è„‰å¯¼ç®¡ï¼ˆPACï¼‰ï¼Œå½»åº•æ”¹å˜äº†æˆ‘ä»¬å¯¹å¿ƒè¾“å‡ºé‡çš„ç›‘æµ‹æ–¹æ³•ï¼Œç®€åŒ–äº†è‚ºåŠ¨è„‰çƒ­ç¨€é‡ŠæŠ€æœ¯ï¼ˆ7ï¼‰ã€‚PAC çš„å¦ä¸€ä¸ªå¥½å¤„æ˜¯å¯ä»¥åŒæ—¶æµ‹é‡å’Œç›‘æµ‹å¤šä¸ªè¡€æµåŠ¨åŠ›å­¦å‚æ•°ï¼ˆè‚ºåŠ¨è„‰å‹ã€è‚ºåŠ¨è„‰é˜»å¡å‹[PAOP]ã€SVR å’Œè‚ºè¡€ç®¡é˜»åŠ›ã€æ ¸å¿ƒä½“æ¸©ã€æ··åˆé™è„‰è¡€æ°§é¥±å’Œåº¦[Svo<sub>2</sub>]ï¼‰ã€‚</p><p>Measurement of the central venous pressure (CVP) had been introduced in the late 1960s, and already provided information on hemodynamic status, notably on right heart filling pressures and thus guidance for rapid fluid administration. However, the CVP does not correlate well with blood volume, as it reflects right ventricular function and venous compliance as well. Use of the PAC helped understand the differences between the CVP and the pulmonary artery wedge or occlusion pressure, which reflects left-sided filling pressures. Interpretation of the pressure waveforms was also promoted, enabling assessment of different conditions affecting the cardiac cycle. ä¸­å¿ƒé™è„‰å‹ï¼ˆCVPï¼‰çš„æµ‹é‡åœ¨ 20 ä¸–çºª 60 å¹´ä»£æœ«è¢«å¼•å…¥ï¼Œå¹¶ä¸”å·²ç»æä¾›äº†å…³äºè¡€æµåŠ¨åŠ›å­¦çŠ¶æ€çš„ä¿¡æ¯ï¼Œç‰¹åˆ«æ˜¯å…³äºå³å¿ƒå……ç›ˆå‹ï¼Œä»è€Œä¸ºå¿«é€Ÿè¾“æ¶²æä¾›æŒ‡å¯¼ã€‚ç„¶è€Œï¼ŒCVP ä¸è¡€å®¹é‡çš„ç›¸å…³æ€§å¹¶ä¸å¥½ï¼Œå› ä¸ºå®ƒä¹Ÿåæ˜ äº†å³å¿ƒå®¤åŠŸèƒ½å’Œé™è„‰é¡ºåº”æ€§ã€‚ä½¿ç”¨ PAC æœ‰åŠ©äºç†è§£ CVP ä¸è‚ºåŠ¨è„‰æ¥”å‹æˆ–è‚ºåŠ¨è„‰é˜»å¡å‹ä¹‹é—´çš„å·®åˆ«ï¼Œåè€…åæ˜ äº†å·¦ä¾§çš„å……ç›ˆå‹ã€‚å®ƒä¹Ÿä¿ƒè¿›äº†å¯¹å‹åŠ›æ³¢å½¢çš„è§£é‡Šï¼Œèƒ½å¤Ÿè¯„ä¼°å½±å“å¿ƒåŠ¨å‘¨æœŸçš„ä¸åŒæƒ…å†µã€‚</p><h3 id="the-concept-of-oxygen-delivery-oxygen-consumption-relationships-and-the-importance-of-svo2-æ°§ä¾›-æ°§è€—å…³ç³»çš„æ¦‚å¿µå’Œ-svo2-çš„é‡è¦æ€§" tabindex="-1"><a class="header-anchor" href="#the-concept-of-oxygen-delivery-oxygen-consumption-relationships-and-the-importance-of-svo2-æ°§ä¾›-æ°§è€—å…³ç³»çš„æ¦‚å¿µå’Œ-svo2-çš„é‡è¦æ€§" aria-hidden="true">#</a> The Concept of Oxygen Delivery/Oxygen Consumption Relationships and the Importance of Svo<sub>2</sub> æ°§ä¾›/æ°§è€—å…³ç³»çš„æ¦‚å¿µå’Œ Svo<sub>2</sub> çš„é‡è¦æ€§</h3><p>Over the years, the emphasis in hemodynamic monitoring has moved progressively from the central to the peripheral circulation, getting closer to the cells. Tissue oxygen consumption (Vo<sub>2</sub>) varies with a patientâ€™s clinical condition (inflammatory response, body temperature, mechanical ventilation, to name a few), and it is essential that sufficient oxygen can be delivered to meet differing cellular needs. Oxygen delivery (Do<sub>2</sub>) is determined by cardiac output and the arterial oxygen content. The concept of providing supranormal amounts of oxygen to avoid the so-called â€œoxygen debtâ€ was promoted in the early 1990s by Shoemaker ( <a href="#R8">8</a> , <a href="#R9">9</a> ) to prevent complications in high-risk surgical patients. However, the excess treatments (e.g., fluids and inotropic therapy) necessary to achieve the marked increase in Do<sub>2</sub> could be harmful in some patients. This was illustrated in a study by Hayes et al ( <a href="#R10">10</a> ) in 1994 using massive doses of dobutamine to achieve the Do<sub>2</sub> goal.</p><p>å¤šå¹´æ¥ï¼Œè¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹çš„é‡ç‚¹å·²ç»é€æ¸ä»ä¸­å¿ƒå¾ªç¯è½¬ç§»åˆ°å¤–å‘¨å¾ªç¯ï¼Œè¶Šæ¥è¶Šæ¥è¿‘ç»†èƒã€‚ç»„ç»‡æ°§è€—ï¼ˆVo<sub>2</sub>ï¼‰éšç—…äººçš„ä¸´åºŠçŠ¶å†µï¼ˆç‚ç—‡ååº”ã€ä½“æ¸©ã€æœºæ¢°é€šæ°”ç­‰ï¼‰è€Œå˜åŒ–ï¼Œå¿…é¡»æœ‰è¶³å¤Ÿçš„æ°§è¾“é€æ¥æ»¡è¶³ä¸åŒçš„ç»†èƒéœ€æ±‚ã€‚æ°§è¾“é€ï¼ˆDo<sub>2</sub>ï¼‰æ˜¯ç”±å¿ƒè¾“å‡ºé‡å’ŒåŠ¨è„‰è¡€æ°§å«é‡å†³å®šçš„ã€‚æä¾›è¶…å¸¸é‡çš„æ°§æ°”ä»¥é¿å…æ‰€è°“çš„ &quot;æ°§å€º &quot;çš„æ¦‚å¿µæ˜¯ç”± Shoemakerï¼ˆ8,9ï¼‰åœ¨ 20 ä¸–çºª 90 å¹´ä»£åˆæå‡ºçš„ï¼Œä»¥é˜²æ­¢é«˜å±æ‰‹æœ¯ç—…äººçš„å¹¶å‘ç—‡ã€‚ç„¶è€Œï¼Œä¸ºå®ç° Do<sub>2</sub> çš„æ˜æ˜¾å¢åŠ è€Œå¿…é¡»è¿›è¡Œçš„è¿‡åº¦æ²»ç–—ï¼ˆå¦‚è¾“æ¶²å’Œæ­£æ€§è‚ŒåŠ›æ²»ç–—ï¼‰åœ¨ä¸€äº›ç—…äººä¸­å¯èƒ½æ˜¯æœ‰å®³çš„ã€‚1994 å¹´ Hayes ç­‰äººï¼ˆ10ï¼‰çš„ä¸€é¡¹ç ”ç©¶è¯´æ˜äº†è¿™ä¸€ç‚¹ï¼Œä»–ä»¬ä½¿ç”¨å¤§é‡çš„å¤šå·´èƒºæ¥è¾¾åˆ° Do<sub>2</sub> çš„ç›®æ ‡ã€‚</p><p>The pendulum therefore shifted toward a more personalized approach, considering the needs of individual patients by using appropriate monitoring. A first strategy consisted of constructing individual Vo<sub>2</sub>/Do<sub>2</sub> curves. Such an approach may make sense because physiologic studies have clearly shown the presence of a Vo<sub>2</sub>/Do<sub>2</sub> dependency phenomenon in shock states ( <a href="#R11">11</a> , <a href="#R12">12</a> ). Furthermore, the fall in Do<sub>2</sub> below a critical value (the so-called Do<sub>2</sub>crit) is associated with an abrupt increase in blood lactate levels (<strong>Fig. 1</strong>). The clinical application of the experimental data was nicely illustrated in the observation by Ronco et al ( <a href="#R13">13</a> ) in 1993 that the same relationship can be documented in patients who die following withdrawal of life-support. However, the individual construction of Vo<sub>2</sub>/Do<sub>2</sub> diagrams in patients has several difficulties. First, it could lead to spurious Vo<sub>2</sub>/Do<sub>2</sub> relationships because of the presence of so-called â€œmathematical coupling of data,â€ in which cardiac output, hemoglobin concentration, and arterial oxygen saturation (Sao<sub>2</sub>) are present on both axes of the graph. To avoid this, it was suggested that Vo<sub>2</sub> be determined by indirect calorimetry, but this does not really provide a â€œmeasuredâ€ Vo<sub>2</sub> just a value estimated using another technique and is prone to other technical limitations ( <a href="#R14">14</a> ). Second, the Vo<sub>2</sub> can change quite rapidly with changes in patient condition or environmental factors.</p><p>å› æ­¤ï¼Œè§‚å¿µè½¬å‘æ›´å…·ä¸ªä½“åŒ–çš„æ–¹æ³•ï¼Œé€šè¿‡æ°å¦‚å…¶åˆ†çš„ç›‘æµ‹æ¥ç”„åˆ«æ‚£è€…çš„éœ€è¦ã€‚ç¬¬ä¸€ä¸ªç­–ç•¥æ˜¯æ„å»ºä¸ªä½“åŒ–çš„ Vo<sub>2</sub>/Do<sub>2</sub> æ›²çº¿ã€‚è¿™ç§æ–¹æ³•å¯èƒ½æ˜¯æœ‰æ„ä¹‰çš„ï¼Œå› ä¸ºç”Ÿç†å­¦ç ”ç©¶å·²ç»æ¸…æ¥šåœ°è¡¨æ˜åœ¨ä¼‘å…‹çŠ¶æ€å­˜åœ¨ Vo<sub>2</sub>/Do<sub>2</sub> ä¾èµ–ç°è±¡ï¼ˆ11,12ï¼‰ã€‚æ­¤å¤–ï¼ŒDo<sub>2</sub> ä¸‹é™åˆ°ä¸€å®šä¸´ç•Œå€¼ä»¥ä¸‹ï¼ˆæ‰€è°“çš„ Do<sub>2</sub>critï¼‰ä¸è¡€ä¹³é…¸æ°´å¹³çš„çªç„¶å‡é«˜æœ‰å…³ï¼ˆå›¾ 1ï¼‰ã€‚ Ronco ç­‰äººï¼ˆ13ï¼‰ 1993 å¹´çš„è§‚å¯Ÿç ”ç©¶ä¸­å¾ˆå¥½çš„éªŒè¯äº†è¿™ä¸€å®éªŒå®¤ç ”ç©¶ç»“æœåœ¨ä¸´åºŠä¸Šçš„æƒ…å†µï¼Œåœ¨ç”Ÿå‘½æ”¯æŒæªæ–½æ’¤é™¤åæ­»äº¡çš„ç—…äººèº«ä¸Šè¯æ˜äº†å­˜åœ¨æœ‰ç›¸åŒçš„å…³ç³»ã€‚ç„¶è€Œï¼Œåœ¨ç»™æ¯ä¸ªç—…äººç»˜åˆ¶ Vo<sub>2</sub>/Do<sub>2</sub> å›¾è¡¨å­˜åœ¨ä¸€äº›å›°éš¾ã€‚é¦–å…ˆï¼Œå®ƒå¯èƒ½å¯¼è‡´è™šå‡çš„ Vo<sub>2</sub>/Do<sub>2</sub> å…³ç³»ï¼Œå› ä¸ºå­˜åœ¨æ‰€è°“çš„ &quot;æ•°æ®çš„æ•°å­¦è€¦åˆ&quot;ï¼Œå³å¿ƒè¾“å‡ºé‡ã€è¡€çº¢è›‹ç™½æµ“åº¦å’ŒåŠ¨è„‰è¡€æ°§é¥±å’Œåº¦ï¼ˆSao<sub>2</sub>ï¼‰åœ¨å›¾è¡¨çš„ä¸¤ä¸ªè½´ä¸Šéƒ½å­˜åœ¨ã€‚ä¸ºäº†é¿å…è¿™ç§æƒ…å†µï¼Œæœ‰äººå»ºè®®ç”¨é—´æ¥çƒ­å¡æµ‹é‡ä»ªæµ‹å®š Vo<sub>2</sub>ï¼Œä½†è¿™å¹¶ä¸èƒ½çœŸæ­£&quot;æµ‹å‡º &quot; Vo<sub>2</sub>ï¼Œåªæ˜¯æ¢äº†ä¸€ç§æŠ€æœ¯çš„ä¼°è®¡å€¼ï¼Œè€Œä¸”å®¹æ˜“å—åˆ°å…¶ä»–æŠ€æœ¯çš„é™åˆ¶ï¼ˆ14ï¼‰ã€‚å…¶æ¬¡ï¼ŒVo<sub>2</sub> å¯ä»¥éšç€ç—…äººçŠ¶å†µæˆ–ç¯å¢ƒå› ç´ çš„å˜åŒ–è€Œè¿…é€Ÿå˜åŒ–ã€‚</p><p>![[Pasted image 20211001175844.png]]</p><p>The relationship between oxygen consumption (Vo<sub>2</sub>) and oxygen delivery (Do<sub>2</sub>). A, Blood lactate levels increase abruptly when Do<sub>2</sub> falls below a critical value (Do<sub>2</sub>crit). Please note that Vo<sub>2</sub> does not fall to the same extent as Do<sub>2</sub> below Do<sub>2</sub>crit, indicating that oxygen extraction can still increase, although to a much lesser extent. B, The same concepts can be represented by a cardiac output/oxygen extraction diagram.</p><p>æ°§è€—ï¼ˆVo<sub>2</sub>ï¼‰å’Œæ°§è¾“é€ï¼ˆDo<sub>2</sub>ï¼‰ä¹‹é—´çš„å…³ç³»ã€‚Aï¼Œå½“ Do<sub>2</sub> ä½äºä¸€å®šä¸´ç•Œå€¼ï¼ˆDo<sub>2</sub>critï¼‰æ—¶ï¼Œè¡€ä¹³é…¸æ°´å¹³å°±ä¼šçªç„¶å¢åŠ ã€‚è¯·æ³¨æ„ï¼Œåœ¨ Do<sub>2</sub>crit ä»¥ä¸‹ï¼ŒVo<sub>2</sub> çš„ä¸‹é™ç¨‹åº¦ä¸ Do<sub>2</sub> çš„ä¸‹é™ç¨‹åº¦ä¸ä¸€æ ·ï¼Œè¿™è¡¨æ˜æ°§çš„æå–ä»ç„¶å¯ä»¥å¢åŠ ï¼Œå°½ç®¡ç¨‹åº¦è¦å°å¾—å¤šã€‚B, åŒæ ·çš„æ¦‚å¿µå¯ä»¥ç”¨å¿ƒè¾“å‡ºé‡/æ°§æ‘„å–å…³ç³»å›¾æ¥è¡¨ç¤ºã€‚</p><p>The relationship between Vo<sub>2</sub> and Do<sub>2</sub> essentially represents oxygen extraction (the ratio of Vo<sub>2</sub>/Do<sub>2</sub>) or more simply the Svo<sub>2</sub> when Sao<sub>2</sub> is close to 100%. The use of the PAC enables easy collection of mixed venous blood from the tip of the catheter in the pulmonary artery. Reference Svo<sub>2</sub> values in acutely ill patients may be a bit lower than the normal value of 75% in healthy humans, because the hemoglobin value in the critically ill is usually lower. Measurement of central venous oxygen saturation (Scvo<sub>2</sub>) through a central venous catheter has been proposed as a surrogate for Svo<sub>2</sub>, but is only an approximation, as venous saturations are not the same in the superior and the inferior parts of the body, and this relationship can be altered by the clinical situation ( <a href="#R15">15</a> ). Hence, Scvo<sub>2</sub> can only be considered as a gross approximation of Svo<sub>2</sub>. Nevertheless, Scvo<sub>2</sub> can still provide valuable information to guide patient management.</p><p>Vo<sub>2</sub> å’Œ Do<sub>2</sub> ä¹‹é—´çš„å…³ç³»åŸºæœ¬ä¸Šä»£è¡¨äº†æ°§æ‘„å–ç‡ï¼ˆVo<sub>2</sub>/Do<sub>2</sub> ä¹‹æ¯”ï¼‰ï¼Œæˆ–è€…æ›´ç®€å•åœ°è¯´ï¼Œå½“ Sao<sub>2</sub> æ¥è¿‘ 100% æ—¶ï¼Œä»£è¡¨äº† Svo<sub>2</sub>ã€‚ä½¿ç”¨ PAC å¯ä»¥æ–¹ä¾¿åœ°ä»è‚ºåŠ¨è„‰çš„å¯¼ç®¡å°–ç«¯æ”¶é›†æ··åˆé™è„‰è¡€ã€‚æ€¥æ€§ç—…æ‚£è€…çš„ Svo<sub>2</sub> å‚è€ƒå€¼å¯èƒ½æ¯”å¥åº·äººæ­£å¸¸å€¼ 75% è¦ä½ä¸€äº›ï¼Œå› ä¸ºå±é‡ç—…äººçš„è¡€çº¢è›‹ç™½é€šå¸¸è¾ƒä½ã€‚æœ‰äººæå‡ºé€šè¿‡ä¸­å¿ƒé™è„‰å¯¼ç®¡æµ‹é‡ä¸­å¿ƒé™è„‰è¡€æ°§é¥±å’Œåº¦ï¼ˆScvo<sub>2</sub>ï¼‰ä½œä¸º Svo<sub>2</sub> çš„æ›¿ä»£å€¼ï¼Œä½†è¿™åªæ˜¯ä¸€ç§è¿‘ä¼¼å€¼ï¼Œå› ä¸ºèº«ä½“ä¸Šéƒ¨å’Œä¸‹éƒ¨çš„é™è„‰è¡€æ°§é¥±å’Œåº¦ä¸ä¸€æ ·ï¼Œè€Œä¸”è¿™ç§å…³ç³»ä¼šå› ä¸´åºŠæƒ…å†µè€Œæ”¹å˜ï¼ˆ15ï¼‰ã€‚å› æ­¤ï¼ŒScvo<sub>2</sub> åªèƒ½è¢«è®¤ä¸ºæ˜¯ Svo<sub>2</sub> çš„ä¸€ä¸ªç²—ç•¥çš„è¿‘ä¼¼å€¼ã€‚å°½ç®¡å¦‚æ­¤ï¼ŒScvo<sub>2</sub> ä»ç„¶å¯ä»¥æä¾›æœ‰ä»·å€¼çš„ä¿¡æ¯æ¥æŒ‡å¯¼ç—…äººç®¡ç†ã€‚</p><p>A suggested approach to interpreting S(c)vo<sub>2</sub> is given in <strong>Figure 2</strong>. Svo<sub>2</sub> can decrease in the presence of decreased arterial oxygen content (due to hypoxemia and/or anemia), an inadequate cardiac output or a significant increase in Vo<sub>2</sub> (e.g., during exercise). It thus became evident that a cardiac output value cannot be correctly interpreted without a simultaneous Svo<sub>2</sub> measurement and vice versa. Importantly, just as a low cardiac output does not need to be corrected in every case, a low Svo<sub>2</sub> should not be corrected in every critically ill patient. This was documented in a large randomized controlled trial (RCT) by Gattinoni et al ( <a href="#R16">16</a> ), in which bringing cardiac output and Svo<sub>2</sub> to normal values did not influence mortality rates. <strong>å›¾ 2</strong> ç»™å‡ºäº†è§£é‡Š S(c)vo<sub>2</sub> çš„å»ºè®®ã€‚åœ¨åŠ¨è„‰å«æ°§é‡ä¸‹é™ï¼ˆç”±äºä½æ°§è¡€ç—‡å’Œ/æˆ–è´«è¡€ï¼‰ã€å¿ƒè¾“å‡ºé‡ä¸è¶³æˆ– Vo<sub>2</sub> æ˜æ˜¾å¢åŠ ï¼ˆä¾‹å¦‚åœ¨è¿åŠ¨ä¸­ï¼‰çš„æƒ…å†µä¸‹ï¼ŒSvo<sub>2</sub> ä¼šä¸‹é™ã€‚å› æ­¤å¾ˆæ˜æ˜¾ï¼Œå¦‚æœæ²¡æœ‰åŒæ—¶æµ‹é‡ Svo<sub>2</sub>ï¼Œå°±ä¸èƒ½æ­£ç¡®è§£é‡Šå¿ƒè¾“å‡ºé‡çš„å€¼ï¼Œåä¹‹äº¦ç„¶ã€‚é‡è¦çš„æ˜¯ï¼Œæ­£å¦‚ä½å¿ƒæ’ä¸éœ€è¦åœ¨æ¯ä¸€ç§æƒ…å†µä¸‹éƒ½å¾—åˆ°çº æ­£ä¸€æ ·ï¼Œä½ Svo<sub>2</sub> ä¹Ÿä¸åº”è¯¥æ˜¯æ¯ä¸€ä¸ªå±é‡ç—…äººéƒ½è¦çº æ­£ã€‚Gattinoni ç­‰äººçš„ä¸€é¡¹å¤§å‹éšæœºå¯¹ç…§è¯•éªŒï¼ˆRCTï¼‰è¯å®è¿™ä¸€ç‚¹ï¼ˆ16ï¼‰ï¼Œå°†å¿ƒè¾“å‡ºé‡å’Œ Svo<sub>2</sub> è°ƒæ•´åˆ°æ­£å¸¸å€¼å¯¹æ­»äº¡ç‡å¹¶æ²¡æœ‰å½±å“ã€‚</p><p>![[Pasted image 20211001182547.png]]</p><p>Interpretation of mixed (central) venous oxygen saturation (S(c)vo<sub>2</sub>). In ovals: things to doâ€”in italic: treatment to consider. CO = cardiac output, PEEP = positive end-expiratory pressure, Sao<sub>2</sub> = arterial oxygen saturation, Vo<sub>2</sub> = oxygen consumption.</p><p>æ··åˆï¼ˆä¸­å¿ƒï¼‰é™è„‰è¡€æ°§é¥±å’Œåº¦ï¼ˆSï¼ˆcï¼‰vo<sub>2</sub>ï¼‰çš„è§£é‡Šã€‚æ¤­åœ†å½¢ï¼šè¦åšçš„äº‹ï¼›æ–œä½“ï¼šè¦è€ƒè™‘çš„æ²»ç–—ã€‚CO=å¿ƒè¾“å‡ºé‡ï¼ŒPEEP=å‘¼æ°”æœ«æ­£å‹ï¼ŒSao<sub>2</sub>=åŠ¨è„‰è¡€æ°§é¥±å’Œåº¦ï¼ŒVo<sub>2</sub>=æ°§è€—ã€‚</p><p>The observation that S(c)vo<sub>2</sub> was low at the time of diagnosis of septic shock in many patients despite traditionally expected to be normal or high following initial resuscitation, led Rivers et al ( <a href="#R17">17</a> ), in 2001, to propose to rapidly (in 6â€‰hr) restore the Scvo<sub>2</sub> to at least 70% in the early resuscitation of such patients. The so-called â€œearly goal-directed therapy (EGDT)â€ was achieved by more aggressive fluid resuscitation and more than three times more patients receiving a blood transfusion compared with control patients. Applied in 130 patients versus 133 in the control group, EGDT was associated with substantially and significantly lower mortality, from 46.5% to 30.5%. This single-center study stimulated strong interest but also some criticism. Three large multicenter RCTs published in 2014 and 2015 ( <a href="#R18">18â€“20</a> ) were unable to reproduce the results but were not true comparator studies of the original study by Rivers et al ( <a href="#R17">17</a> ), notably including patients who were less severely ill and most of the patients in the EGDT group had normal S(c)vo<sub>2</sub> values at the start of the EGDT strategy ( <a href="#R21">21</a> ). Hence, application of this strategy cannot be considered as evidence-based, but it does not invalidate the importance of S(c)vo<sub>2</sub> in interpreting hemodynamic status in patients who do not improve promptly ( <a href="#R22">22</a> ).</p><p>è§‚å¯Ÿåˆ°è®¸å¤šç—…äººåœ¨è¯Šæ–­è„“æ¯’ç—‡ä¼‘å…‹æ—¶çš„ S(c)vo<sub>2</sub> å¾ˆä½ï¼Œå°½ç®¡ä¼ ç»Ÿä¸Šé¢„è®¡åœ¨æœ€åˆå¤è‹åä¼šæ­£å¸¸æˆ–å¾ˆé«˜ï¼Œè¿™ä½¿å¾— Rivers ç­‰äººï¼ˆ17ï¼‰åœ¨ 2001 å¹´æå‡ºåœ¨æ­¤ç±»ç—…äººçš„æ—©æœŸå¤è‹ä¸­è¿…é€Ÿï¼ˆ6 å°æ—¶å†…ï¼‰å°† Scvo<sub>2</sub> æ¢å¤åˆ°è‡³å°‘ 70%ã€‚é€šè¿‡æ›´ç§¯æçš„æ¶²ä½“å¤è‹æ¥è¾¾åˆ°æ‰€è°“çš„ &quot;æ—©æœŸç›®æ ‡å¯¼å‘æ²»ç–—ï¼ˆEGDTï¼‰&quot;ï¼Œä¸å¯¹ç…§ç»„æ‚£è€…ç›¸æ¯”ï¼Œæ¥å—è¾“è¡€çš„æ‚£è€…å¤šäº†ä¸‰å€ã€‚åœ¨ 130 åæ‚£è€…ä¸­åº”ç”¨ EGDTï¼Œè€Œå¯¹ç…§ç»„ä¸º 133 åï¼ŒEGDT å¤§å¹…é™ä½äº†æ­»äº¡ç‡ï¼Œä» 46.5% é™è‡³ 30.5%ã€‚è¿™é¡¹å•ä¸­å¿ƒç ”ç©¶å¼•èµ·äº†æå¤§å…´è¶£ï¼Œä½†ä¹Ÿæœ‰ä¸€äº›æ‰¹è¯„ã€‚2014 å¹´å’Œ 2015 å¹´å‘è¡¨çš„ä¸‰é¡¹å¤§å‹å¤šä¸­å¿ƒ RCTç ”ç©¶ï¼ˆ18-20ï¼‰éƒ½æ— æ³•é‡ç°æ”¹ç»“æœï¼Œä½†å®ƒä»¬å¹¶ä¸æ˜¯ Rivers ç­‰äººï¼ˆ17ï¼‰åŸå§‹ç ”ç©¶çš„çœŸæ­£çš„å¯¹æ¯”ç ”ç©¶ï¼Œç‰¹åˆ«æ˜¯åœ¨çº³å…¥äº†ç—…æƒ…ä¸é‡çš„æ‚£è€…ï¼Œè€Œä¸” EGDT ç»„çš„å¤§å¤šæ•°æ‚£è€…åœ¨ EGDT ç­–ç•¥å¼€å§‹æ—¶ Sï¼ˆcï¼‰vo<sub>2</sub> çš„å€¼æ˜¯æ­£å¸¸çš„ï¼ˆ21ï¼‰ã€‚å› æ­¤ï¼Œåº”ç”¨è¿™ä¸€ç­–ç•¥ä¸èƒ½è¢«è®¤ä¸ºæ˜¯å¾ªè¯çš„ï¼Œä½†è¿™å¹¶ä¸æ„å‘³ç€å°±å¦å®šäº†å¯¹ç—…æƒ…æœªè¿…é€Ÿæ”¹å–„çš„æ‚£è€…ç”¨ S(c)vo<sub>2</sub> æ¥è§£é‡Šè¡€æµåŠ¨åŠ›å­¦çŠ¶æ€çš„é‡è¦æ€§(22)ã€‚</p><p>The addition of the venoarterial Pco<sub>2</sub> (VAPco<sub>2</sub>) gradient may be useful in the presence of persisting hemodynamic alterations when the Svo<sub>2</sub> is normal or high. In these conditions, an increased VAPco<sub>2</sub> gradient greater than 6â€‰mm Hg may indicate that peripheral blood flow is still inadequate ( <a href="#R23">23</a> ).</p><p>å½“ Svo<sub>2</sub> æ­£å¸¸æˆ–å‡é«˜æ—¶ï¼Œè¿›ä¸€æ­¥æŸ¥çœ‹é™è„‰-åŠ¨è„‰ Pco<sub>2</sub>ï¼ˆVAPco<sub>2</sub>ï¼‰æ¢¯åº¦å¯èƒ½å¯¹åˆ¤æ–­è¡€æµåŠ¨åŠ›å­¦æ”¹å˜æŒç»­å­˜åœ¨æ˜¯æœ‰ç”¨çš„ã€‚åœ¨è¿™äº›æƒ…å†µä¸‹ï¼ŒVAPco<sub>2</sub> æ¢¯åº¦å‡é«˜å¤§äº 6 æ¯«ç±³æ±æŸ±å¯èƒ½è¡¨æ˜å¤–å‘¨è¡€æµä»ç„¶ä¸è¶³ï¼ˆ23ï¼‰ã€‚</p><h3 id="blood-lactate-concentrations-è¡€ä¹³é…¸æµ“åº¦" tabindex="-1"><a class="header-anchor" href="#blood-lactate-concentrations-è¡€ä¹³é…¸æµ“åº¦" aria-hidden="true">#</a> Blood Lactate Concentrations è¡€ä¹³é…¸æµ“åº¦</h3><p>In shock, falling tissue oxygen concentrations result in anaerobic metabolism with the increased formation of lactate, making blood lactate concentration a useful index of altered tissue perfusion ( <a href="#R24">24</a> ). This recognition was an important step in the evolution of hemodynamic monitoring. Based on the fundamental studies of Huckabee on the relationship between pyruvate and lactate (25â€“ <a href="#R27">27</a> ), Broder and Weil ( <a href="#R28">28</a> ) proposed in 1969 that excess lactate should be measured to assess the role of â€œoxygen debtâ€ in prognostication of shock states. The concept of oxygen debt was challenged, however, as it is more relevant to the field of strenuous exercise, and the measurements of pyruvate are too complex and cumbersome to become routinely used in clinical practice. Numerous articles have focused on the pathophysiology of lactic acidosis in septic shock, emphasizing that hyperlactatemia is not due only to cellular hypoxia, but other cellular derangements can be involved ( <a href="#R24">24</a> ). Nevertheless, blood lactate concentrations are well-established as an index of the severity of shock ( <a href="#R29">29</a> ) and hyperlactatemia (&gt; 1.5â€“2 mmol/L) as a marker of poor outcome.</p><p>ä¼‘å…‹æ—¶ï¼Œç»„ç»‡æ°§æµ“åº¦ä¸‹é™å¯¼è‡´æ— æ°§ä»£è°¢ï¼Œä¹³é…¸ç”Ÿæˆå¢åŠ ï¼Œä½¿è¡€ä¹³é…¸æµ“åº¦æˆä¸ºç»„ç»‡çŒæ³¨æ”¹å˜çš„æœ‰ç”¨æŒ‡æ ‡ï¼ˆ24ï¼‰ã€‚è¿™ä¸€è®¤è¯†æ˜¯è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å‘å±•ä¸­çš„é‡è¦ä¸€æ­¥ã€‚åŸºäº Huckabee å¯¹ä¸™é…®é…¸å’Œä¹³é…¸å…³ç³»çš„åŸºæœ¬ç ”ç©¶ï¼ˆ25-27ï¼‰ï¼ŒBroder å’Œ Weilï¼ˆ28ï¼‰åœ¨ 1969 å¹´æå‡ºåº”å¯¹è¿‡é‡çš„ä¹³é…¸è¿›è¡Œæµ‹é‡ä»¥è¯„ä¼° &quot;æ°§å€º &quot;åˆ¤æ–­ä¼‘å…‹é¢„åçš„ä½œç”¨ã€‚ç„¶è€Œï¼Œæ°§å€ºçš„æ¦‚å¿µå­˜æœ‰è´¨ç–‘ï¼Œå› ä¸ºå®ƒæ›´å¤šçš„æ˜¯ä¸å‰§çƒˆè¿åŠ¨æ–¹é¢æœ‰å…³ï¼Œè€Œä¸™é…®é…¸çš„æµ‹é‡è¿‡äºå¤æ‚å’Œç¹çä¸èƒ½ä½œä¸ºå¸¸è§„ç”¨äºä¸´åºŠã€‚ä¸“æ³¨äºè„“æ¯’ç—‡ä¼‘å…‹ä¹³é…¸é…¸ä¸­æ¯’ç—…ç†ç”Ÿç†å­¦æ–¹é¢çš„å¾ˆå¤šæ–‡çŒ®å¼ºè°ƒé«˜ä¹³é…¸è¡€ç—‡ä¸ä»…æ˜¯ç”±äºç»†èƒç¼ºæ°§ï¼Œè¿˜å¯èƒ½æ¶‰åŠå…¶ä»–ç»†èƒæ°´å¹³å¤±è°ƒï¼ˆ24ï¼‰ã€‚å°½ç®¡å¦‚æ­¤ï¼Œè¡€ä¹³é…¸æµ“åº¦ä½œä¸ºä¼‘å…‹ä¸¥é‡ç¨‹åº¦çš„æŒ‡æ ‡ï¼ˆ29ï¼‰ä»¥åŠé«˜ä¹³é…¸è¡€ç—‡ï¼ˆ&gt;1.5-2 mmol/Lï¼‰ä½œä¸ºé¢„åä¸ä½³çš„æŒ‡æ ‡å·²ç»å¾—åˆ°å…¬è®¤ã€‚</p><p>The concept of measuring serial blood lactate concentrations over time to monitor patient response to treatment and evolution soon emerged. In early studies in the 1980s, blood lactate concentrations were shown to decrease by 10% over one hour in the most straightforward patients with circulatory shock who responded to fluid administration ( <a href="#R30">30</a> ). Further studies confirmed that a rapid decrease in lactate concentration is associated with a better prognosis in various groups of critically ill patients ( <a href="#R31">31</a> ). As lactate concentrations reflect the balance between production and clearance (primarily by the liver), the term â€œlactate clearanceâ€ is not appropriate to describe lactate kinetics ( <a href="#R32">32</a> ). Development of rapid bedside analyzers has simplified measurement of lactate concentrations. Treatment based primarily on lactate kinetics ( <a href="#R33">33</a> ) has been attempted but this approach is not entirely convincing, because the changes in lactate concentrations are slow ( <a href="#R31">31</a> ). Hence, the assessment of serial blood lactate levels is considered as helpful to assess the response to therapy rather than to precisely guide it ( <a href="#R24">24</a> ).</p><p>éšæ—¶é—´è¿ç»­å¤šæ¬¡æµ‹é‡è¡€ä¹³é…¸æµ“åº¦æ¥ç›‘æµ‹ç—…äººå¯¹æ²»ç–—çš„ååº”å’Œç—…æƒ…è¿›å±•çš„æ¦‚å¿µå¾ˆå¿«å‡ºç°äº†ã€‚åœ¨ 20 ä¸–çºª 80 å¹´ä»£çš„æ—©æœŸç ”ç©¶ä¸­ï¼Œå¯¹æ˜æ˜¾è¡¥æ¶²æœ‰ååº”çš„å¾ªç¯æ€§ä¼‘å…‹æ‚£è€…ï¼Œæ˜¾ç¤ºè¡€ä¹³é…¸æµ“åº¦ä¸€å°æ—¶å†…ä¸‹é™äº† 10%ï¼ˆ30ï¼‰ã€‚è¿›ä¸€æ­¥çš„ç ”ç©¶è¯å®ï¼Œè¡€ä¹³é…¸æµ“åº¦å¿«é€Ÿä¸‹é™çš„å„ç»„å±é‡æ‚£è€…å…¶é¢„åéƒ½æ›´å¥½ï¼ˆ31ï¼‰ã€‚ç”±äºä¹³é…¸æµ“åº¦åæ˜ äº†ä¹³é…¸çš„ç”Ÿæˆå’Œæ¸…é™¤ï¼ˆä¸»è¦ç”±è‚è„æ¸…é™¤ï¼‰ä¹‹é—´çš„å¹³è¡¡ï¼Œ&quot;ä¹³é…¸æ¸…é™¤ &quot;ä¸€è¯ä¸é€‚åˆæè¿°ä¹³é…¸åŠ¨åŠ›å­¦ï¼ˆ32ï¼‰ã€‚å¿«é€ŸåºŠæ—åˆ†æä»ªçš„å‡ºç°ç®€åŒ–äº†ä¹³é…¸æ°´å¹³çš„æ£€æµ‹ã€‚å°è¯•é‡‡ç”¨ä¸»è¦åŸºäºä¹³é…¸åŠ¨åŠ›å­¦çš„æ²»ç–—åï¼ˆ33ï¼‰ï¼Œå‘ç°è¯¥æ–¹æ³•ä¸å°½å¦‚äººæ„ï¼Œå› ä¸ºä¹³é…¸æµ“åº¦çš„å˜åŒ–å¾ˆæ…¢ï¼ˆ31ï¼‰ã€‚å› æ­¤ï¼Œè¿ç»­è¯„ä¼°è¡€ä¹³é…¸æ°´å¹³è¢«è®¤ä¸ºæœ‰åŠ©äºè¯„ä¼°ç–—æ•ˆï¼Œä½†ä¸èƒ½ç²¾ç¡®æŒ‡å¯¼æ²»ç–—ï¼ˆ24ï¼‰ã€‚</p><h3 id="the-importance-of-peripheral-perfusion-å¤–å‘¨çŒæ³¨çš„é‡è¦æ€§" tabindex="-1"><a class="header-anchor" href="#the-importance-of-peripheral-perfusion-å¤–å‘¨çŒæ³¨çš„é‡è¦æ€§" aria-hidden="true">#</a> The Importance of Peripheral Perfusion å¤–å‘¨çŒæ³¨çš„é‡è¦æ€§</h3><p>The attempt to selectively increase the regional blood flow to some organs has led to increased interest in monitoring regional blood flow, but this is difficult in the clinical setting. Measurements of blood flow in the hepatosplanchnic circulation are possible but quite invasive ( <a href="#R34">34</a> ). Gastric tonometry became popular in the 1990s. This minimally invasive technique assesses gastric mucosal perfusion via a modified nasogastric tube equipped with a balloon including some saline or even Co<sub>2</sub>. Monitoring of critically ill patients using this technique was shown to decrease mortality in a study published in 1992 ( <a href="#R35">35</a> ), but the existence of many artifacts leading to inconsistent results led to this approach being abandoned. More recently, measurements of urethral perfusion have also been proposed ( <a href="#R36">36</a> ). Studying the peripheral blood flow to the extremities could be valuable. Joly and Weil ( <a href="#R37">37</a> ) proposed already in 1969 to monitor the toe temperature, but this strategy is limited in the presence of peripheral arteriopathy. The assessment of skin perfusion has been pursued by different techniques, from the simple capillary refill time ( <a href="#R38">38</a> ) to the more complex use of Doppler techniques ( <a href="#R39">39</a> ). Assessment of peripheral perfusion has been, and will remain, an important component of the clinical evaluation of the critically ill.</p><p>æƒ³è¦é€‰æ‹©æ€§çš„å¢åŠ ä¸€äº›å™¨å®˜å±€éƒ¨è¡€æµçš„å°è¯•è®©äººå¯¹å±€éƒ¨è¡€æµç›‘æµ‹æ›´æ„Ÿå…´è¶£ï¼Œä½†è¿™åœ¨ä¸´åºŠä¸Šæ˜¯å¾ˆå›°éš¾çš„ã€‚æµ‹é‡è‚è„¾å¾ªç¯çš„è¡€æµåˆ°æ˜¯æœ‰å¯èƒ½ï¼Œä½†ä¾µå…¥æ€§è¾ƒå¤§ï¼ˆ34ï¼‰ã€‚20 ä¸–çºª 90 å¹´ä»£ï¼Œèƒƒå¼ åŠ›æµ‹é‡æ³•å¼€å§‹æµè¡Œã€‚è¿™ç§å¾®åˆ›æŠ€æœ¯é€šè¿‡å¸¦æœ‰çƒå›Šçš„æ”¹è‰¯é¼»èƒƒç®¡æ¥è¯„ä¼°èƒƒç²˜è†œçŒæ³¨ï¼Œçƒå›Šå†…å«æœ‰ä¸€å®šé‡çš„ç”Ÿç†ç›æ°´ç”šæˆ– Co<sub>2</sub> ã€‚1992 å¹´å‘è¡¨çš„ä¸€é¡¹ç ”ç©¶æ˜¾ç¤ºï¼Œä½¿ç”¨è¿™ç§æŠ€æœ¯ç›‘æµ‹å±é‡ç—…äººå¯é™ä½æ­»äº¡ç‡ï¼ˆ35ï¼‰ï¼Œä½†ç”±äºå­˜åœ¨è®¸å¤šä¼ªå·®å¯¼è‡´ç»“æœä¸ä¸€è‡´ï¼Œå› æ­¤è¿™ç§æ–¹æ³•è¢«æ”¾å¼ƒäº†ã€‚æœ€è¿‘ï¼Œä¹Ÿæœ‰äººæå‡ºäº†æµ‹é‡å°¿é“çŒæ³¨çš„æ–¹æ³•ï¼ˆ36ï¼‰ã€‚ç ”ç©¶æµå‘å››è‚¢çš„å¤–å‘¨è¡€æµå¯èƒ½æ˜¯æœ‰ä»·å€¼çš„ã€‚Joly å’Œ Weilï¼ˆ37ï¼‰åœ¨ 1969 å¹´å·²ç»æå‡ºç›‘æµ‹è„šè¶¾æ¸©åº¦ï¼Œä½†è¿™ç§æ–¹æ³•åœ¨æœ‰å¤–å‘¨åŠ¨è„‰ç—…å˜æ—¶ä»·å€¼æœ‰é™ã€‚æœ‰å¤šç§æ–¹æ³•è¯„ä¼°çš®è‚¤çŒæ³¨ï¼Œä»ç®€å•çš„æ¯›ç»†è¡€ç®¡å†å……ç›ˆæ—¶é—´ï¼ˆ38ï¼‰åˆ°æ›´å¤æ‚çš„å¤šæ™®å‹’è¶…å£°æŠ€æœ¯çš„ä½¿ç”¨ï¼ˆ39ï¼‰ã€‚å¤–å‘¨è¡€æµçŒæ³¨çš„è¯„ä¼°ä¸€ç›´æ˜¯å¹¶å°†ç»§ç»­æ˜¯å±é‡ç—…äººä¸´åºŠè¯„ä¼°çš„ä¸€ä¸ªé‡è¦ç»„æˆéƒ¨åˆ†ã€‚</p><h3 id="the-importance-of-the-microcirculation-å¾®å¾ªç¯çš„é‡è¦æ€§" tabindex="-1"><a class="header-anchor" href="#the-importance-of-the-microcirculation-å¾®å¾ªç¯çš„é‡è¦æ€§" aria-hidden="true">#</a> The Importance of the Microcirculation å¾®å¾ªç¯çš„é‡è¦æ€§</h3><p>Restoring and maintaining adequate tissue oxygenation is the ultimate goal of hemodynamic resuscitation and management. Estimation of Do<sub>2</sub> includes the components cardiac output, hemoglobin, and Sao<sub>2</sub>, but this neglects not only the distribution of cardiac output to the various organs but also distribution within the organs. Several methods exist to explore the microcirculation ( <a href="#R40">40</a> ), including laser Doppler that measures RBC speed in small tissues, intravital microvideo-surface microscopy applied directly on organs, microvideo-surface microscopy by orthogonal polarization spectral or sidestream darkfield imaging, and nail capillarovideoscopy. For clinical practice, one needs the devices to be reliable and reproducible, easy to use, and which provide data that are easy to interpret by most medical and paramedical staff ( <a href="#R41">41</a> ).</p><p>æ¢å¤å’Œç»´æŒè¶³å¤Ÿçš„ç»„ç»‡æ°§åˆæ˜¯è¡€æµåŠ¨åŠ›å­¦å¤è‹å’Œç®¡ç†çš„æœ€ç»ˆç›®æ ‡ã€‚å¯¹ Do<sub>2</sub> çš„è¯„ä¼°åŒ…æ‹¬å¿ƒè¾“å‡ºé‡ã€è¡€çº¢è›‹ç™½å’Œ Sao<sub>2</sub> ç­‰ç»„æˆéƒ¨åˆ†ï¼Œä½†è¿™ä¸ä»…æœªè€ƒè™‘å¿ƒè¾“å‡ºé‡åœ¨å„å™¨å®˜çš„åˆ†å¸ƒï¼Œä¹Ÿæœªè€ƒè™‘å™¨å®˜å†…çš„åˆ†å¸ƒã€‚æœ‰å‡ ç§æ–¹æ³•å¯ä»¥æ¢ç©¶å¾®å¾ªç¯ï¼ˆ40ï¼‰ï¼ŒåŒ…æ‹¬æµ‹é‡å°å—ç»„ç»‡ä¸­ RBC é€Ÿåº¦çš„æ¿€å…‰å¤šæ™®å‹’ï¼Œç›´æ¥ç”¨äºå™¨å®˜çš„æ´»ä½“å¾®è§†é¢‘-è¡¨é¢æ˜¾å¾®é•œï¼ˆå¾®è§†é¢‘-è¡¨é¢æ˜¾å¾®é•œé‡‡ç”¨æ­£äº¤åæŒ¯å…‰è°±æˆ–ä¾§æµæš—åœºæˆåƒæŠ€æœ¯ï¼‰ï¼Œä»¥åŠæŒ‡ç”²æ¯›ç»†è¡€ç®¡è§†é¢‘æ£€æŸ¥ã€‚å¯¹äºä¸´åºŠå®è·µï¼Œäººä»¬éœ€è¦è¿™äº›è®¾å¤‡æ˜¯å¯é çš„ã€å¯é‡å¤çš„ã€æ˜“äºä½¿ç”¨çš„ï¼Œè€Œä¸”æä¾›çš„æ•°æ®å¯¹å¤§å¤šæ•°åŒ»åŠ¡äººå‘˜å’Œå‡†åŒ»åŠ¡äººå‘˜æ¥è¯´æ˜¯å®¹æ˜“è§£é‡Šçš„ï¼ˆ41ï¼‰ã€‚</p><p>Handheld vital microscopy assessing the sublingual microcirculation has been the most widely studied approach and has enabled persistent microcirculatory alterations to be depicted in critically ill patients with sepsis ( <a href="#R42">42</a> ). The time course of these changes has been associated with organ dysfunction and mortality ( <a href="#R43">43</a> ) and microvascular changes are frequently observed even after global variables have normalized ( <a href="#R43">43</a> , <a href="#R44">44</a> ). This approach has been used to assess the effects of various interventions on the microcirculation, including the titration of vasopressor support ( <a href="#R45">45</a> ). Whether these measurements can be used to adjust treatment such that they have an impact on patient outcome remains to be proven.</p><p>è¯„ä¼°èˆŒä¸‹å¾®å¾ªç¯çš„æ‰‹æŒå¼ç”Ÿå‘½æ˜¾å¾®é•œæ˜¯ç ”ç©¶æœ€å¹¿æ³›çš„æ–¹æ³•ï¼Œå®ƒèƒ½å¤Ÿå±•ç¤ºè„“æ¯’ç—‡é‡ç—‡æ‚£è€…æŒç»­å­˜åœ¨çš„å¾®å¾ªç¯æ”¹å˜ï¼ˆ42ï¼‰ã€‚è¿™äº›æ”¹å˜çš„æ—¶é—´è¿‡ç¨‹ä¸å™¨å®˜åŠŸèƒ½éšœç¢å’Œæ­»äº¡ç‡æœ‰å…³ï¼ˆ43ï¼‰ï¼Œå³ä½¿åœ¨å…¨å±€å‚æ•°æ¢å¤æ­£å¸¸åï¼Œä¹Ÿç»å¸¸èƒ½è§‚å¯Ÿåˆ°å¾®è¡€ç®¡æœ‰å˜åŒ–ï¼ˆ43,44ï¼‰ã€‚è¿™ç§æ–¹æ³•å·²è¢«ç”¨äºè¯„ä¼°å„ç§å¹²é¢„æªæ–½å¯¹å¾®å¾ªç¯çš„å½±å“ï¼ŒåŒ…æ‹¬å¾ªç¯æ”¯æŒæ—¶æ»´å®šå‡å‹è¯ç‰©ï¼ˆ45ï¼‰ã€‚è¿™äº›æµ‹é‡ç»“æœæ˜¯å¦å¯ä»¥ç”¨æ¥è°ƒæ•´æ²»ç–—ï¼Œä»è€Œå¯¹ç—…äººçš„é¢„åäº§ç”Ÿå½±å“ï¼Œè¿˜æœ‰å¾…è¯æ˜ã€‚</p><h3 id="the-move-toward-less-invasive-techniques-æœç€å¾®åˆ›æŠ€æœ¯å‘å±•" tabindex="-1"><a class="header-anchor" href="#the-move-toward-less-invasive-techniques-æœç€å¾®åˆ›æŠ€æœ¯å‘å±•" aria-hidden="true">#</a> The Move Toward Less Invasive Techniques æœç€å¾®åˆ›æŠ€æœ¯å‘å±•</h3><h4 id="decreasing-use-of-the-pac-pac-çš„ä½¿ç”¨åœ¨å‡å°‘ã€‚" tabindex="-1"><a class="header-anchor" href="#decreasing-use-of-the-pac-pac-çš„ä½¿ç”¨åœ¨å‡å°‘ã€‚" aria-hidden="true">#</a> Decreasing Use of the PAC. PAC çš„ä½¿ç”¨åœ¨å‡å°‘ã€‚</h4><p>The use of the PAC has decreased worldwide over the last 2 decades. One argument to support this trend was that RCTs have not consistently shown a reduction in mortality associated with the use of PACs ( <a href="#R46">46â€“48</a> ). However, a reduction in mortality has not been shown with other monitoring techniques (<strong>Table 1</strong>), such as the electrocardiogram or pulse oximetry ( <a href="#R49">49</a> ), for example, but these are still widely used. Gastric tonometry was shown to influence mortality ( <a href="#R35">35</a> ), and yet this technique has been abandoned. Furthermore, a monitoring technique can only improve outcomes if the data generated can be used to influence management in a way that can reduce mortality. Hence, the negative observations from the RCTs suggest that PAC-derived measurements cannot influence patient management and/or that the changes in management do not influence mortality. The reduced use of the PAC in recent years is likely explained more by the greater availability and use of echo-Doppler techniques and other newer, less invasive hemodynamic monitoring techniques. Although these newer devices have reduced the use of PAC-derived monitoring, PAC-derived variables remain of value in certain complex patients, particularly those with severe cardiorespiratory failure ( <a href="#R60">60</a> ).</p><p>åœ¨è¿‡å»çš„ 20 å¹´é‡Œï¼Œå…¨ä¸–ç•Œ PAC çš„ä½¿ç”¨å·²ç»å‡å°‘äº†ã€‚æ”¯æŒè¿™ä¸€è¶‹åŠ¿çš„ä¸€ä¸ªè®ºç‚¹æ˜¯ï¼ŒRCTs ç ”ç©¶æ²¡æœ‰ä¸€è‡´æ€§æ˜¾ç¤ºå‡ºä½¿ç”¨ PACs èƒ½å¸¦æ¥æ­»äº¡ç‡çš„ä¸‹é™ï¼ˆ46-48ï¼‰ã€‚ç„¶è€Œï¼Œå…¶ä»–ç›‘æµ‹æŠ€æœ¯ï¼ˆè¡¨ 1ï¼‰ä¹Ÿæ²¡æœ‰æ˜¾ç¤ºå‡ºæ­»äº¡ç‡çš„é™ä½ï¼Œä¾‹å¦‚å¿ƒç”µå›¾æˆ–è„‰æè¡€æ°§ä»ªï¼ˆ49ï¼‰ï¼Œä½†å®ƒä»¬ä»è¢«å¹¿æ³›ä½¿ç”¨ã€‚èƒƒå¼ åŠ›æµ‹é‡æ³•è¢«è¯æ˜ä¼šå½±å“æ­»äº¡ç‡ï¼ˆ35ï¼‰ï¼Œç„¶è€Œè¿™ç§æŠ€æœ¯å·²ç»è¢«æ”¾å¼ƒäº†ã€‚æ­¤å¤–ï¼Œä¸€ç§ç›‘æµ‹æŠ€æœ¯åªæœ‰åœ¨å…¶äº§ç”Ÿçš„æ•°æ®ä»¥èƒ½å¤Ÿé™ä½æ­»äº¡ç‡çš„æ–¹å¼æ¥å½±å“æ‚£è€…ç®¡ç†æ—¶æ‰ä¼šæ”¹å–„é¢„åã€‚å› æ­¤ï¼ŒRCTs çš„é˜´æ€§ç»“æœè¡¨æ˜ï¼ŒPAC è¡ç”Ÿçš„æµ‹é‡ç»“æœä¸èƒ½å½±å“ç—…äººçš„ç®¡ç†ï¼Œå’Œ/æˆ–ç®¡ç†ä¸Šçš„æ”¹å˜ä¸èƒ½å½±å“æ­»äº¡ç‡ã€‚è¿‘å¹´æ¥ï¼ŒPAC çš„ä½¿ç”¨å‡å°‘ï¼Œå¯èƒ½æ›´å¤šçš„æ˜¯ç”±äºè¶…å£°å¤šæ™®å‹’æŠ€æœ¯å’Œå…¶ä»–è¾ƒæ–°çš„ã€å¾®åˆ›è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹æŠ€æœ¯çš„æ™®åŠå’Œä½¿ç”¨ã€‚è™½ç„¶è¿™äº›æ›´æ–°çš„è®¾å¤‡å‡å°‘äº† PAC çš„ä½¿ç”¨ï¼Œä½† PAC å‚æ•°å¯¹æŸäº›å¤æ‚çš„ç—…äººï¼Œç‰¹åˆ«æ˜¯é‚£äº›ä¸¥é‡å¿ƒè‚ºè¡°ç«­çš„ç—…äººä»æœ‰ä»·å€¼ï¼ˆ60ï¼‰ã€‚</p><div class="article-table"><a id="T1"></a><div class="article-table-title"><span>TABLE 1. - </span> Some Hemodynamic Strategies That Have Been Studied in Randomized Controlled Trials in Critically Ill Patients But Failed to Show a Reduction in Mortality<em class="fa fa-arrows-alt expand-button js-expand-table-event" aria-label="expand table"></em><div class="clearfix"></div></div><div class="scroll-message"></div><div class="dummy-scroll"><div></div></div><div class="article-table-body"><div class="article-table-container"><table><thead xmlns="http://www.w3.org/1999/xhtml"><tr><th align="left" rowspan="1" colspan="1" class="column-1st">Strategy</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody xmlns="http://www.w3.org/1999/xhtml"><tr><td align="left" colspan="2" rowspan="1" class="column-1st">In critically ill patients (in general)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒHigher vs lower mixed venous â€ƒoxygen saturation targets in critically ill patients</td><td align="left" rowspan="1" colspan="1">Gattinoni et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R16">16</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒHigher vs lower cardiac output â€ƒin critically ill patients</td><td align="left" rowspan="1" colspan="1">Gattinoni et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R16">16</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒHigher vs lower hemoglobin â€ƒtargets for blood transfusion</td><td align="left" rowspan="1" colspan="1">HÃ©bert et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R50">50</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒThe <span class="ej-keyword" data-value="pulmonary artery catheter">pulmonary artery catheter</span></td><td align="left" rowspan="1" colspan="1">Sandham et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R48">48</a></sup>), Richard et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R51">51</a></sup>), Harvey et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R52">52</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒColloids vs crystalloids</td><td align="left" rowspan="1" colspan="1">Myburgh et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R53">53</a></sup>), Annane et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R54">54</a></sup>)</td></tr><tr><td align="left" colspan="2" rowspan="1" class="column-1st">In septic patients (in particular)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒVasopressin administration</td><td align="left" rowspan="1" colspan="1">Russell et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R55">55</a></sup>), Gordon et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R56">56</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒHigher vs lower hemoglobin â€ƒtargets for blood transfusion</td><td align="left" rowspan="1" colspan="1">Holst et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R57">57</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒHigher vs lower arterial â€ƒpressure targets</td><td align="left" rowspan="1" colspan="1">Asfar et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R58">58</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒEarly goal-directed therapy</td><td align="left" rowspan="1" colspan="1">Yealy et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R18">18</a></sup>), Peake et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R19">19</a></sup>), Mouncey et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R20">20</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒLevosimendan administration</td><td align="left" rowspan="1" colspan="1">Gordon et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R59">59</a></sup>)</td></tr></tbody></table><div class="article-table-descriptions" style="width:100%;"></div></div></div></div><div class="article-table"><a id="T1"></a><div class="article-table-title"><span>è¡¨ 1. - </span> é‡ç—‡æ‚£è€…RCTç ”ç©¶æœªèƒ½è¯å®èƒ½å¤Ÿé™ä½ç—…æ­»ç‡çš„è¡€æµåŠ¨åŠ›å­¦ç­–ç•¥<em class="fa fa-arrows-alt expand-button js-expand-table-event" aria-label="expand table"></em><div class="clearfix"></div></div><div class="scroll-message"></div><div class="dummy-scroll"><div></div></div><div class="article-table-body"><div class="article-table-container"><table><thead xmlns="http://www.w3.org/1999/xhtml"><tr><th align="left" rowspan="1" colspan="1" class="column-1st">ç­–ç•¥</th><th align="center" rowspan="1" colspan="1">å‚è€ƒæ–‡çŒ®</th></tr></thead><tbody xmlns="http://www.w3.org/1999/xhtml"><tr><td align="left" colspan="2" rowspan="1" class="column-1st">é’ˆå¯¹é‡ç—‡æ‚£è€…(æ€»ä½“)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒé‡ç—‡æ‚£è€…æ··åˆé™è„‰è¡€æ°§é¥±å’Œåº¦é«˜ä½ç›®æ ‡å¯¹æ¯”</td><td align="left" rowspan="1" colspan="1">Gattinoni et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R16">16</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒé‡ç—‡æ‚£è€…å¿ƒè¾“å‡ºé‡é«˜ä½å¯¹æ¯”</td><td align="left" rowspan="1" colspan="1">Gattinoni et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R16">16</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒè¾“è¡€æ—¶è¡€çº¢è›‹ç™½ç›®æ ‡é«˜ä½å¯¹æ¯”</td><td align="left" rowspan="1" colspan="1">HÃ©bert et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R50">50</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒè‚ºåŠ¨è„‰å¯¼ç®¡ </td><td align="left" rowspan="1" colspan="1">Sandham et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R48">48</a></sup>), Richard et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R51">51</a></sup>), Harvey et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R52">52</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒèƒ¶ä½“æ¶²å’Œæ™¶ä½“æ¶²æ¯”è¾ƒ</td><td align="left" rowspan="1" colspan="1">Myburgh et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R53">53</a></sup>), Annane et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R54">54</a></sup>)</td></tr><tr><td align="left" colspan="2" rowspan="1" class="column-1st">é’ˆå¯¹è„“æ¯’ç—‡æ‚£è€… (ç‰¹å®š)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒå‡å‹è¯ç‰©çš„ä½¿ç”¨</td><td align="left" rowspan="1" colspan="1">Russell et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R55">55</a></sup>), Gordon et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R56">56</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒè¾“è¡€æ—¶è¡€çº¢è›‹ç™½ç›®æ ‡é«˜ä½å¯¹æ¯”</td><td align="left" rowspan="1" colspan="1">Holst et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R57">57</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒåŠ¨è„‰å‹ç›®æ ‡é«˜ä½å¯¹æ¯”</td><td align="left" rowspan="1" colspan="1">Asfar et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R58">58</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒæ—©æœŸç›®æ ‡å¯¼å‘æ²»ç–—ï¼ˆEGDTï¼‰</td><td align="left" rowspan="1" colspan="1">Yealy et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R18">18</a></sup>), Peake et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R19">19</a></sup>), Mouncey et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R20">20</a></sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1" class="column-1st">â€ƒå·¦è¥¿å­Ÿæ—¦çš„ä½¿ç”¨</td><td align="left" rowspan="1" colspan="1">Gordon et al (<sup xmlns=""><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="R59">59</a></sup>)</td></tr></tbody></table><div class="article-table-descriptions" style="width:100%;"></div></div></div></div><p>Some Hemodynamic Strategies That Have Been Studied in Randomized Controlled Trials in Critically Ill Patients But Failed to Show a Reduction in Mortality</p><p>ä¸€äº›é’ˆå¯¹é‡ç—‡æ‚£è€…å¼€å±•è¿‡éšæœºå¯¹ç…§è¯•éªŒçš„è¡€æµåŠ¨åŠ›å­¦ç­–ç•¥ï¼Œä½†ç»“æœæœªèƒ½é™ä½æ­»äº¡ç‡ã€‚</p><h4 id="the-development-of-echo-doppler-è¶…å£°å¤šæ™®å‹’çš„å‘å±•ã€‚" tabindex="-1"><a class="header-anchor" href="#the-development-of-echo-doppler-è¶…å£°å¤šæ™®å‹’çš„å‘å±•ã€‚" aria-hidden="true">#</a> The Development of Echo-Doppler.è¶…å£°å¤šæ™®å‹’çš„å‘å±•ã€‚</h4><p>It is beyond the scope of this review to discuss the echo-Doppler technique in detail. Echo-Doppler, first developed in the 1950s but only becoming more widely used clinically in the 1970s ( <a href="#R61">61</a> ), was initially reserved for use in cardiology, but the development of simplified, more mobile devices and availability of training programs around the globe have enabled echo-Doppler to be used routinely in many ICUs. It is not necessary to be an expert in echo-Doppler to use it in the management of critically ill patients; knowledge and expertise can be relatively limited, covering just the necessary basics to perform a so-called focused cardiac ultrasound ( <a href="#R62">62</a> ); cardiologists can still be called if more complex evaluations are needed. Echocardiography can differentiate between the different types of shock ( <a href="#R2">2</a> ) and serial examination can be used to monitor response to treatment.</p><p>è¶…å£°å¤šæ™®å‹’æŠ€æœ¯çš„è¯¦ç»†è®¨è®ºä¸åœ¨æœ¬æ–‡èŒƒå›´ã€‚è¶…å£°å¤šæ™®å‹’æœ€æ—©æ˜¯åœ¨ 20 ä¸–çºª 50 å¹´ä»£å‡ºç°çš„ï¼Œä½†åœ¨ 20 ä¸–çºª 70 å¹´ä»£æ‰å¼€å§‹åœ¨ä¸´åºŠä¸Šå¹¿æ³›ä½¿ç”¨ï¼ˆ61ï¼‰ï¼Œæœ€åˆåªç”¨äºå¿ƒè„ç—…ï¼Œä½†éšç€è®¾å¤‡æ›´ç®€å•ã€ä¾¿æºä»¥åŠå…¨çƒå„åœ°åŸ¹è®­é¡¹ç›®çš„å¼€å±•ï¼Œä½¿è¶…å£°å¤šæ™®å‹’åœ¨è®¸å¤š ICU ä¸­å¾—åˆ°äº†å¸¸è§„åº”ç”¨ã€‚åœ¨å±é‡ç—…äººçš„ç®¡ç†ä¸­ï¼Œä¸ä¸€å®šè¦æˆä¸ºè¶…å£°å¤šæ™®å‹’çš„ä¸“å®¶ï¼›ç›¸å¯¹æœ‰é™çš„è¶…å£°ä¸“ä¸šçŸ¥è¯†å°±è¡Œï¼Œåªéœ€æŒæ¡å¿…è¦çš„åŸºç¡€çŸ¥è¯†å°±èƒ½è¿›è¡Œæ‰€è°“çš„é‡ç‚¹å¿ƒè„è¶…å£°æ£€æŸ¥ï¼ˆ62ï¼‰ï¼›å¦‚æœéœ€è¦æ›´å¤æ‚çš„è¯„ä¼°ï¼Œä»ç„¶å¯ä»¥è¯·å¿ƒè„ç§‘åŒ»ç”Ÿæ¥ã€‚è¶…å£°å¿ƒåŠ¨å›¾å¯ä»¥å¯¹ä¸åŒç±»å‹çš„ä¼‘å…‹è¿›è¡Œé‰´åˆ«è¯Šæ–­ï¼ˆ2ï¼‰ï¼Œè¿ç»­è¶…å£°æ£€æŸ¥å¯ç”¨äºç›‘æµ‹æ²»ç–—çš„ååº”æ€§ã€‚</p><h4 id="availability-of-less-invasive-methods-for-cardiac-output-measurement-æµ‹é‡å¿ƒè¾“å‡ºé‡çš„ç°æœ‰å¾®åˆ›æŠ€æœ¯ã€‚" tabindex="-1"><a class="header-anchor" href="#availability-of-less-invasive-methods-for-cardiac-output-measurement-æµ‹é‡å¿ƒè¾“å‡ºé‡çš„ç°æœ‰å¾®åˆ›æŠ€æœ¯ã€‚" aria-hidden="true">#</a> Availability of Less Invasive Methods for Cardiac Output Measurement. æµ‹é‡å¿ƒè¾“å‡ºé‡çš„ç°æœ‰å¾®åˆ›æŠ€æœ¯ã€‚</h4><p>Other indicator dilution methods to measure cardiac output were developed to avoid the need for a PAC (<strong>Fig. 3</strong>), including transpulmonary thermodilution and lithium dilution ( <a href="#R63">63â€“65</a> ). However, a (central) venous catheter is still required for indicator injection and an arterial catheter to detect changes in indicator temperature or concentration.</p><p>å·²å‘æ˜çš„ä¸ç”¨ PAC çš„æŒ‡ç¤ºå‰‚ç¨€é‡Šæ³•æµ‹é‡å¿ƒè¾“å‡ºé‡çš„å…¶ä»–æ–¹æ³•åŒ…æ‹¬ç»è‚ºçƒ­ç¨€é‡Šæ³•å’Œé”‚ç¨€é‡Šæ³•ï¼ˆå›¾ 3ï¼‰ï¼ˆ63-65ï¼‰ã€‚ç„¶è€Œï¼Œä»ç„¶éœ€è¦ä¸€æ ¹ï¼ˆä¸­å¿ƒï¼‰é™è„‰å¯¼ç®¡æ¥æ³¨å°„æŒ‡ç¤ºå‰‚ï¼Œä»¥åŠä¸€æ ¹åŠ¨è„‰å¯¼ç®¡æ¥æ£€æµ‹æŒ‡ç¤ºå‰‚çš„æ¸©åº¦æˆ–æµ“åº¦çš„å˜åŒ–ã€‚</p><p>![[Pasted image 20211002055148.png|1000]]</p><p>Timeline showing the development of some techniques to measure or estimate cardiac output</p><p>ä¸€äº›æµ‹é‡æˆ–ä¼°æµ‹å¿ƒè¾“å‡ºé‡æŠ€æœ¯çš„ç ”å‘æ—¶é—´çº¿</p><p>Pulse wave analysis, which uses a mathematical analysis of the arterial blood pressure waveform to estimate cardiac output, has also been proposed ( <a href="#R66">66</a> , <a href="#R67">67</a> ). With pulse wave analysis, cardiac output is estimated continuously, with a rapid response time; it can therefore be used to assess fluid responsiveness during, for example, a fluid challenge maneuver or a passive leg raising test. However, estimation of cardiac output using pulse wave analysis relies on theoretical assumptions and measurement performance is limited in patients with rapid changes in vasomotor tone, either spontaneous or drug-induced. Different pulse wave analysis devicesâ€”invasive, minimally invasive, and noninvasiveâ€”are available for this purpose, and may use external, internal, or no calibration to calibrate the estimated cardiac output values ( <a href="#R66">66</a> ). Each has benefits and limitations, but detailed discussion is beyond the scope of this article (<strong>Table 2</strong>).</p><p>è„‰ææ³¢å½¢åˆ†æï¼Œä½¿ç”¨åŠ¨è„‰è¡€å‹æ³¢å½¢çš„æ•°å­¦åˆ†ææ¥ä¼°è®¡å¿ƒè¾“å‡ºé‡ï¼Œä¹Ÿå·²è¢«æå‡ºï¼ˆ66,67ï¼‰ã€‚é€šè¿‡è„‰ææ³¢å½¢åˆ†æï¼Œå¯ä»¥è¿ç»­ä¼°è®¡å¿ƒè¾“å‡ºé‡ï¼Œååº”æ—¶é—´å¿«ï¼›å› æ­¤ï¼Œå®ƒå¯ä»¥ç”¨æ¥è¯„ä¼°æ¶²ä½“ååº”æ€§ï¼Œä¾‹å¦‚åœ¨å¿«é€Ÿè¡¥æ¶²æˆ–è¢«åŠ¨æŠ¬è…¿è¯•éªŒä¸­ã€‚ç„¶è€Œï¼Œä½¿ç”¨è„‰ææ³¢å½¢åˆ†æä¼°è®¡å¿ƒè¾“å‡ºé‡ä¾èµ–äºç†è®ºä¸Šçš„å‡è®¾ï¼Œåœ¨è¡€ç®¡å¼ åŠ›å¿«é€Ÿå˜åŒ–çš„ç—…äººä¸­ï¼Œæ— è®ºæ˜¯è‡ªå‘çš„è¿˜æ˜¯è¯ç‰©å¼•èµ·çš„ï¼Œæµ‹é‡æ€§èƒ½éƒ½ä¼šå—é™ã€‚ä¸åŒçš„è„‰ææ³¢å½¢åˆ†æè®¾å¤‡-æœ‰åˆ›çš„ã€å¾®åˆ›çš„å’Œæ— åˆ›çš„-éƒ½å¯ç”¨äºæ­¤ç›®çš„ï¼Œå¹¶å¯ä½¿ç”¨å¤–éƒ¨ã€å†…éƒ¨æ ¡å‡†è£…ç½®æˆ–æ— éœ€æ ¡å‡†è£…ç½®å¯¹ä¼°æµ‹çš„å¿ƒè¾“å‡ºé‡å€¼è¿›è¡Œæ ¡å‡†ï¼ˆ66ï¼‰ã€‚æ¯ä¸€ç§éƒ½æœ‰å…¶å¥½å¤„å’Œå±€é™æ€§ï¼Œæœ¬æ–‡ä¸åšè¯¦ç»†è®¨è®ºï¼ˆè¡¨ 2ï¼‰ã€‚</p><div class="article-table"><a id="T2"></a><div class="article-table-title"><span>TABLE 2. - </span> Advantages and Limitations of Techniques for Cardiac Output Determination<em class="fa fa-arrows-alt expand-button js-expand-table-event" aria-label="expand table"></em><div class="clearfix"></div></div><div class="scroll-message"></div><div class="dummy-scroll"><div></div></div><div class="article-table-body"><div class="article-table-container"><table><thead xmlns="http://www.w3.org/1999/xhtml"><tr><th align="left" rowspan="1" colspan="1" class="column-1st">Method</th><th align="center" rowspan="1" colspan="1">Advantages</th><th align="center" rowspan="1" colspan="1">Limitations</th></tr></thead><tbody xmlns="http://www.w3.org/1999/xhtml"><tr><td align="left" rowspan="3" colspan="1" class="column-1st">Pulmonary artery â€ƒthermodilution</td><td align="left" rowspan="1" colspan="1">Clinical reference method</td><td align="left" rowspan="1" colspan="1">Invasiveness, catheter-related major complications</td></tr><tr><td align="left" rowspan="2" colspan="1">Additional variables: cardiac filling pressures and mixed venous oxygen saturation</td><td align="left" rowspan="1" colspan="1">Sources of error including the temperature and volume of the injectate, timing of indicator injection during respiratory cycle</td></tr><tr><td align="left" rowspan="1" colspan="1">Measurement error in patients with intracardiac shunts and tricuspid valve abnormalities</td></tr><tr><td align="left" colspan="3" rowspan="1" class="column-1st">Transpulmonary indicator dilution</td></tr><tr><td align="left" rowspan="2" colspan="1" class="column-1st">â€ƒThermodilution</td><td align="left" rowspan="1" colspan="1">Good performance</td><td align="left" rowspan="2" colspan="1">Invasiveness, complications associated with central venous and (femoral) arterial catheters</td></tr><tr><td align="left" rowspan="1" colspan="1">Additional variables: volumetric preload variables, extravascular lung water and pulmonary vascular permeability index</td></tr><tr><td align="left" rowspan="4" colspan="1" class="column-1st">â€ƒLithium dilution</td><td align="left" rowspan="4" colspan="1">Good performance</td><td align="left" rowspan="1" colspan="1">Invasiveness</td></tr><tr><td align="left" rowspan="1" colspan="1">Response time</td></tr><tr><td align="left" rowspan="1" colspan="1">Costs</td></tr><tr><td align="left" rowspan="1" colspan="1">Not available everywhere</td></tr><tr><td align="left" rowspan="5" colspan="1" class="column-1st">Minimally invasive pulse wave analysis</td><td align="left" rowspan="1" colspan="1">No external calibration</td><td align="left" rowspan="1" colspan="1">Depends on impeccable blood pressure waveform quality</td></tr><tr><td align="left" rowspan="1" colspan="1">Beat-to-beat continuous monitoring</td><td align="left" rowspan="1" colspan="1">Stroke volume algorithms based on theoretical assumptions</td></tr><tr><td align="left" rowspan="1" colspan="1">Operator independent</td><td valign="top" rowspan="3" colspan="1">Marked alterations or rapid changes in systemic vascular resistance make cardiac output estimations unreliable (e.g., in patients with shock)</td></tr><tr><td align="left" rowspan="1" colspan="1">Plug and play (easy to set up)</td></tr><tr><td align="left" rowspan="1" colspan="1">Additional variables: stroke volume variation/pulse pressure variation</td></tr><tr><td align="left" rowspan="5" colspan="1" class="column-1st">Transesophageal Doppler</td><td align="left" rowspan="5" colspan="1">Beat-to-beat continuous cardiac output monitoring</td><td align="left" rowspan="1" colspan="1">Operator dependent</td></tr><tr><td align="left" rowspan="1" colspan="1">Probe not fixed: frequent need for repositioning</td></tr><tr><td align="left" rowspan="1" colspan="1">Sedation and mechanical ventilation required</td></tr><tr><td align="left" rowspan="1" colspan="1">Assumes constant distribution of arterial blood flow between the upper and lower parts of the body</td></tr><tr><td align="left" rowspan="1" colspan="1">Depends on the correct estimation of the diameter of the aorta</td></tr><tr><td align="left" rowspan="5" colspan="1" class="column-1st">Finger cuff method (noninvasive pulse wave analysis)</td><td align="left" rowspan="1" colspan="1">No external calibration</td><td align="left" rowspan="1" colspan="1">Not reliable in presence of finger edema and poor peripheral perfusion</td></tr><tr><td align="left" rowspan="1" colspan="1">Beat-to-beat continuous cardiac output monitoring</td><td valign="top" rowspan="4" colspan="1">Poor performance, especially in the presence of vasoconstriction</td></tr><tr><td align="left" rowspan="1" colspan="1">Operator independent</td></tr><tr><td align="left" rowspan="1" colspan="1">Plug and play (easy to set up)</td></tr><tr><td align="left" rowspan="1" colspan="1">Additional variables: SVV/PPV</td></tr><tr><td align="left" rowspan="3" colspan="1" class="column-1st">Pulse wave transit time</td><td align="left" rowspan="1" colspan="1">No need for calibration</td><td align="left" rowspan="1" colspan="1">Not reliable in the presence of arrhythmia</td></tr><tr><td align="left" rowspan="1" colspan="1">Operator independent</td><td align="left" rowspan="1" colspan="1">Not reliable if vasoconstriction</td></tr><tr><td align="left" rowspan="1" colspan="1">Plug and play (easy to set up)</td><td align="left" rowspan="1" colspan="1">Does not provide SVV/PPV</td></tr><tr><td align="left" rowspan="3" colspan="1" class="column-1st">Thoracic bioimpedance and bioreactance</td><td align="left" rowspan="1" colspan="1">No calibration</td><td align="left" rowspan="1" colspan="1">Unreliable in many cases of arrhythmia, electrical interference, internal or external pacemakers, movement (motion artifacts), anatomic shunts, pleural and pericardial effusions, foreign bodies in the chest, pulmonary edema</td></tr><tr><td align="left" rowspan="1" colspan="1">Operator independent</td><td valign="top" rowspan="2" colspan="1">Electrode positioning (interference with some surgical sites)</td></tr><tr><td align="left" rowspan="1" colspan="1">Plug and play (easy to set up)</td></tr></tbody></table><div class="article-table-descriptions" style="width:100%;"><div class="article-table-descriptions-content"><span id=""><div class="dib">PPV = pulse pressure variation, SVV = stroke volume variation.</div></span></div></div></div></div></div><div class="article-table"><a id="T2"></a><div class="article-table-title"><span>è¡¨ 2. - </span> å¿ƒè¾“å‡ºé‡æµ‹å®šæŠ€æœ¯çš„ä¼˜ç¼ºç‚¹<em class="fa fa-arrows-alt expand-button js-expand-table-event" aria-label="expand table"></em><div class="clearfix"></div></div><div class="scroll-message"></div><div class="dummy-scroll"><div></div></div><div class="article-table-body"><div class="article-table-container"><table><thead xmlns="http://www.w3.org/1999/xhtml"><tr><th align="left" rowspan="1" colspan="1" class="column-1st">æ–¹æ³•</th><th align="center" rowspan="1" colspan="1">ä¼˜ç‚¹</th><th align="center" rowspan="1" colspan="1">ç¼ºç‚¹</th></tr></thead><tbody xmlns="http://www.w3.org/1999/xhtml"><tr><td align="left" rowspan="3" colspan="1" class="column-1st">è‚ºåŠ¨è„‰çƒ­ç¨€é‡Š</td><td align="left" rowspan="1" colspan="1">ä¸´åºŠå‚è€ƒæ–¹æ³•</td><td align="left" rowspan="1" colspan="1">æœ‰åˆ›ï¼Œå¯¼ç®¡ç›¸å…³çš„ä¸»è¦å¹¶å‘ç—‡</td></tr><tr><td align="left" rowspan="2" colspan="1">é¢å¤–å‚æ•°ï¼šå¿ƒè„å……ç›ˆå‹å’Œæ··åˆé™è„‰è¡€æ°§é¥±å’Œåº¦</td><td align="left" rowspan="1" colspan="1">è¯¯å·®æ¥æºåŒ…æ‹¬æ³¨å°„å‰‚çš„æ¸©åº¦å’Œé‡ï¼Œåœ¨å‘¼å¸å‘¨æœŸä¸­æŒ‡ç¤ºå‰‚æ³¨å°„çš„æ—¶æœº</td></tr><tr><td align="left" rowspan="1" colspan="1">å¿ƒå†…åˆ†æµå’Œä¸‰å°–ç“£å¼‚å¸¸æ‚£è€…å­˜åœ¨æµ‹é‡è¯¯å·®</td></tr><tr><td align="left" colspan="3" rowspan="1" class="column-1st">ç»è‚ºæŒ‡ç¤ºå‰‚ç¨€é‡Š</td></tr><tr><td align="left" rowspan="2" colspan="1" class="column-1st">â€ƒçƒ­ç¨€é‡Š</td><td align="left" rowspan="1" colspan="1">è¡¨ç°ä¼˜å¼‚</td><td align="left" rowspan="2" colspan="1">æœ‰åˆ›ï¼Œä¸­å¿ƒé™è„‰å’Œï¼ˆè‚¡ï¼‰åŠ¨è„‰å¯¼ç®¡ç›¸å…³å¹¶å‘ç—‡</td></tr><tr><td align="left" rowspan="1" colspan="1">é¢å¤–å‚æ•°ï¼šå‰è´Ÿè·å®¹é‡å‚æ•°ï¼Œè¡€ç®¡å¤–è‚ºæ°´ä»¥åŠè‚ºè¡€ç®¡é€šé€æŒ‡æ•°</td></tr><tr><td align="left" rowspan="4" colspan="1" class="column-1st">â€ƒé”‚ç¨€é‡Š</td><td align="left" rowspan="4" colspan="1">è¡¨ç°ä¼˜å¼‚</td><td align="left" rowspan="1" colspan="1">æœ‰åˆ›</td></tr><tr><td align="left" rowspan="1" colspan="1">ååº”æ—¶é—´</td></tr><tr><td align="left" rowspan="1" colspan="1">è´¹ç”¨</td></tr><tr><td align="left" rowspan="1" colspan="1">å¹¶éåœ¨å“ªå„¿éƒ½èƒ½ç”¨</td></tr><tr><td align="left" rowspan="5" colspan="1" class="column-1st">å¾®åˆ›è„‰ææ³¢å½¢åˆ†æ</td><td align="left" rowspan="1" colspan="1">æ— éœ€é¢å¤–æ ¡å‡†</td><td align="left" rowspan="1" colspan="1">å–å†³äºè´¨é‡å¥½çš„è¡€å‹æ³¢å½¢</td></tr><tr><td align="left" rowspan="1" colspan="1">æŒç»­æ£€æµ‹æ¯æ¬¡å¿ƒè·³</td><td align="left" rowspan="1" colspan="1">æ ¹æ®ç†è®ºå‡è®¾è®¡ç®—æ¯æé‡</td></tr><tr><td align="left" rowspan="1" colspan="1">æ— æ“ä½œè€…ä¾èµ–æ€§</td><td valign="top" rowspan="3" colspan="1">å¤–å‘¨è¡€ç®¡é˜»åŠ›æ˜¾è‘—æˆ–è¿…é€Ÿå˜åŒ–å¯¼è‡´å¿ƒè¾“å‡ºé‡çš„ä¼°è®¡ä¸å¯é ï¼ˆå¦‚ï¼Œä¼‘å…‹æ‚£è€…ï¼‰</td></tr><tr><td align="left" rowspan="1" colspan="1">å³æ’å³ç”¨ (æ˜“äºå»ºç«‹)</td></tr><tr><td align="left" rowspan="1" colspan="1">é¢å¤–å‚æ•°ï¼šæ¯æé‡å˜å¼‚ï¼ˆSVVï¼‰/è„‰æå‹å˜å¼‚ï¼ˆPPVï¼‰</td></tr><tr><td align="left" rowspan="5" colspan="1" class="column-1st">ç»é£Ÿé“è¶…å£°</td><td align="left" rowspan="5" colspan="1">é€æ¬¡å¿ƒæå¿ƒè¾“å‡ºé‡æ£€æµ‹</td><td align="left" rowspan="1" colspan="1">æ“ä½œè€…ä¾èµ–æ€§</td></tr><tr><td align="left" rowspan="1" colspan="1">æ¢å¤´ä¸å›ºå®šï¼šç»å¸¸éœ€è¦å¤ä½</td></tr><tr><td align="left" rowspan="1" colspan="1">éœ€è¦é•‡é™å’Œæœºæ¢°é€šæ°”</td></tr><tr><td align="left" rowspan="1" colspan="1">å‡è®¾èº«ä½“ä¸Šä¸‹éƒ¨åˆ†çš„åŠ¨è„‰è¡€æµåˆ†å¸ƒæ˜¯ä¸å˜çš„</td></tr><tr><td align="left" rowspan="1" colspan="1">å–å†³äºå¯¹ä¸»åŠ¨è„‰ç›´å¾„ä¼°è®¡å€¼çš„æ ¡å‡†</td></tr><tr><td align="left" rowspan="5" colspan="1" class="column-1st">æŒ‡å¥—æ³•ï¼ˆæ— åˆ›è„‰ææ³¢å½¢åˆ†æï¼‰</td><td align="left" rowspan="1" colspan="1">wuxué¢å¤–æ ¡å‡†</td><td align="left" rowspan="1" colspan="1">æ‰‹æŒ‡æ°´è‚¿å’Œå¤–å‘¨çŒæ³¨ä¸è‰¯æ—¶ä¸å¯é </td></tr><tr><td align="left" rowspan="1" colspan="1">é€æ¬¡å¿ƒæå¿ƒè¿ç»­è¾“å‡ºé‡ç›‘æµ‹</td><td valign="top" rowspan="4" colspan="1">è¡¨ç°ä¸ä½³ï¼Œå°¤å…¶æ˜¯æœ‰è¡€ç®¡æ”¶ç¼©æ—¶</td></tr><tr><td align="left" rowspan="1" colspan="1">æ— æ“ä½œè€…ä¾èµ–æ€§</td></tr><tr><td align="left" rowspan="1" colspan="1">å³æ’å³ç”¨(æ˜“äºå»ºç«‹ï¼‰</td></tr><tr><td align="left" rowspan="1" colspan="1">é¢å¤–å‚æ•°ï¼šSVV/PPV</td></tr><tr><td align="left" rowspan="3" colspan="1" class="column-1st">è„‰ææ³¢å½¢ä¼ æ’­æ—¶é—´</td><td align="left" rowspan="1" colspan="1">æ— éœ€æ ¡å‡†</td><td align="left" rowspan="1" colspan="1">å¿ƒå¾‹å¤±å¸¸æ—¶ä¸å¯é </td></tr><tr><td align="left" rowspan="1" colspan="1">æ— æ“ä½œè€…ä¾èµ–æ€§</td><td align="left" rowspan="1" colspan="1">å¦‚æœè¡€ç®¡æ”¶ç¼©åˆ™ä¸å¯é </td></tr><tr><td align="left" rowspan="1" colspan="1">å³æ’å³ç”¨ï¼ˆæ˜“äºå»ºç«‹ï¼‰</td><td align="left" rowspan="1" colspan="1">ä¸èƒ½æä¾› SVV/PPV</td></tr><tr><td align="left" rowspan="3" colspan="1" class="column-1st">ç»èƒ¸ç”Ÿç‰©é˜»æŠ—å’Œç”Ÿç‰©ç”µæŠ—</td><td align="left" rowspan="1" colspan="1">æ— éœ€æ ¡å‡†</td><td align="left" rowspan="1" colspan="1">è®¸å¤šæƒ…å†µä¸‹ä¸å¯é ï¼Œå¦‚å¿ƒå¾‹å¤±å¸¸ã€ç”µæ°”å¹²æ‰°ã€å¿ƒå†…æˆ–èƒ¸å¤–èµ·æã€è¿åŠ¨ï¼ˆè¿åŠ¨ä¼ªå·®ï¼‰ã€è§£å‰–åˆ†æµã€èƒ¸è…”ç§¯æ¶²å’Œå¿ƒåŒ…ç§¯æ¶²ã€èƒ¸å†…å¼‚ç‰©ã€è‚ºæ°´è‚¿</td></tr><tr><td align="left" rowspan="1" colspan="1">æ— æ“ä½œè€…ä¾èµ–æ€§</td><td valign="top" rowspan="2" colspan="1">ç‚¹å‡»ä½ç½®ï¼ˆå—åˆ°ä¸€äº›æ‰‹æœ¯éƒ¨ä½çš„å½±å“ï¼‰</td></tr><tr><td align="left" rowspan="1" colspan="1">å³æ’å³ç”¨ï¼ˆæ˜“äºå»ºç«‹ï¼‰</td></tr></tbody></table><div class="article-table-descriptions" style="width:100%;"><div class="article-table-descriptions-content"><span id=""><div class="dib">PPV = è„‰æå‹å˜å¼‚, SVV = æ¯æé‡å˜å¼‚ã€‚</div></span></div></div></div></div></div><p>Advantages and Limitations of Techniques for Cardiac Output Determination</p><p>å¿ƒè¾“å‡ºé‡æµ‹é‡æŠ€æœ¯çš„ä¼˜ç¼ºç‚¹</p><p>Other less invasive methods for cardiac output monitoring, including noninvasive pulse wave analysis (e.g., finger cuff method), pulse wave transit time, Co<sub>2</sub> rebreathing, thoracic bioimpedance and bioreactance, are not reliable enough for routine use in critically ill patients.</p><p>å…¶ä»–ç›‘æµ‹å¿ƒè¾“å‡ºé‡çš„å¾®åˆ›æŠ€æœ¯ï¼ŒåŒ…æ‹¬æ— åˆ›è„‰ææ³¢å½¢åˆ†æï¼ˆå¦‚æŒ‡å¥—æ³•ï¼‰ã€è„‰ææ³¢ä¼ è¾“æ—¶é—´ã€Co<sub>2</sub> é‡å¤å¸å…¥ã€èƒ¸è…”ç”Ÿç‰©é˜»æŠ—å’Œç”Ÿç‰©ç”µæŠ—ç­‰ï¼Œåœ¨å±é‡ç—…äººçš„å¸¸è§„ä½¿ç”¨ä¸Šä¸å¤Ÿå¯é ã€‚</p><h2 id="hemodynamic-monitoring-during-administration-of-key-therapeutic-interventions-in-shock-ä¼‘å…‹è¿›è¡Œå…³é”®æ²»ç–—å¹²é¢„æ—¶çš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹" tabindex="-1"><a class="header-anchor" href="#hemodynamic-monitoring-during-administration-of-key-therapeutic-interventions-in-shock-ä¼‘å…‹è¿›è¡Œå…³é”®æ²»ç–—å¹²é¢„æ—¶çš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹" aria-hidden="true">#</a> HEMODYNAMIC MONITORING DURING ADMINISTRATION OF KEY THERAPEUTIC INTERVENTIONS IN SHOCK ä¼‘å…‹è¿›è¡Œå…³é”®æ²»ç–—å¹²é¢„æ—¶çš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹</h2><p>As proposed by Weil and Shubin (68) many years ago, the patient with shock should be managed according to the Ventilate, Infuse, Pump approach. Each of these management components requires close and specific hemodynamic monitoring.</p><p>æ­£å¦‚ Weil å’Œ Shubin(68)å¤šå¹´å‰æå‡ºçš„ï¼Œä¼‘å…‹æ‚£è€…åº”æŒ‰ç…§é€šæ°”ã€è¾“æ¶²ã€æ³µï¼ˆVIPï¼‰çš„æ–¹æ³•è¿›è¡Œç®¡ç†ã€‚è¿™äº›ç®¡ç†çš„æ¯ä¸€ä¸ªéƒ¨åˆ†éƒ½éœ€è¦ä¸¥å¯†å’Œç‰¹å®šçš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹ã€‚</p><h3 id="ventilate-é€šæ°”" tabindex="-1"><a class="header-anchor" href="#ventilate-é€šæ°”" aria-hidden="true">#</a> Ventilate é€šæ°”</h3><p>It may not seem intuitive that hemodynamic management requires an initial focus on ventilation, but an adequate oxygen supply is essential to restore an adequate Do<sub>2</sub>. The use of invasive mechanical ventilation can decrease the oxygen demand of the respiratory muscles, thus facilitating achievement of adequate tissue Do<sub>2</sub>. Optimal timing of endotracheal intubation is thus an important part of the resuscitation process.</p><p>è¡€æµåŠ¨åŠ›å­¦ç®¡ç†è¦æ±‚ä¸€å¼€å§‹å°±å…³æ³¨é€šæ°”ï¼Œè¿™ä¼¼ä¹æœ‰è¿ç›´è§‰ï¼Œä½†å……è¶³çš„æ°§æ°”ä¾›åº”å¯¹äºæ¢å¤è¶³å¤Ÿçš„ Do<sub>2</sub> æ˜¯è‡³å…³é‡è¦çš„ã€‚ä½¿ç”¨æœ‰åˆ›æœºæ¢°é€šæ°”å¯ä»¥å‡å°‘å‘¼å¸è‚Œçš„éœ€æ°§é‡ï¼Œä»è€Œæœ‰åˆ©äºå®ç°è¶³å¤Ÿçš„ç»„ç»‡ Do<sub>2</sub>ã€‚å› æ­¤ï¼Œæ°”ç®¡æ’ç®¡çš„æœ€ä½³æ—¶æœºæ˜¯å¤è‹è¿‡ç¨‹çš„ä¸€ä¸ªéå¸¸é‡è¦çš„ç»„æˆéƒ¨åˆ†ã€‚</p><h3 id="infuse-è¾“æ¶²" tabindex="-1"><a class="header-anchor" href="#infuse-è¾“æ¶²" aria-hidden="true">#</a> Infuse è¾“æ¶²</h3><p>Fluid administration remains an essential component of the management of all forms of shock. Initially reserved for hypovolemic states, and to some extent septic shock, fluid administration is also essential in cardiogenic shock, because the vasoconstrictive state results in extravasation of fluid into the interstitium. Hence, management of cardiogenic shock using prudent fluid administration has become a standard, even when cardiogenic lung edema is present ( <a href="#R69">69</a> ).</p><p>è¾“æ¶²ä»ç„¶æ˜¯æ‰€æœ‰ä¼‘å…‹ç®¡ç†ä¸­çš„ä¸€ä¸ªé‡è¦ç»„æˆéƒ¨åˆ†ã€‚æœ€åˆåªç”¨äºä½è¡€å®¹é‡çŠ¶æ€ï¼Œä»¥åŠæŸäº›è„“æ¯’ç—‡ä¼‘å…‹ï¼Œä½†åœ¨å¿ƒæºæ€§ä¼‘å…‹ï¼Œè¾“æ¶²ä¹Ÿæ˜¯å¿…ä¸å¯å°‘çš„ï¼Œå› ä¸ºè¡€ç®¡æ”¶ç¼©çŠ¶æ€ä¼šå¯¼è‡´æ¶²ä½“å¤–æ¸—åˆ°é—´è´¨ä¸­ã€‚å› æ­¤ï¼Œå³ä½¿å­˜åœ¨å¿ƒæºæ€§è‚ºæ°´è‚¿ï¼Œè°¨æ…è¡¥æ¶²å·²ç»æˆä¸ºå¿ƒæºæ€§ä¼‘å…‹ç®¡ç†çš„æ ‡å‡†ï¼ˆ69ï¼‰ã€‚</p><p>How much fluid should be given has been a topic of intense discussion. Attempts to predetermine the amount of fluid required have been unsuccessful in all subsets of patients. Hence, the amount of fluid to be given should be guided by appropriate and adequate hemodynamic monitoring in individual patients. Monitoring arterial pressure alone may be sufficient when vascular tone is well preserved, but in septic shock the cardiac output may increase much more than the arterial pressure ( <a href="#R70">70</a> ), so that a cardiac output measurement is desirable. Although a low CVP can increase confidence that fluid administration will be safe, a single CVP measurement is not a reliable indicator of fluid requirements ( <a href="#R71">71</a> ). Changes in CVP during the administration of a fluid bolus provide more useful information about the tolerance to fluids. The benefit (increase in cardiac output) versus risk (of edema formation) of fluid is the basis for the fluid challenge technique, in which a relatively small amount of fluids (usually around 200â€‰mL) is given over a relatively short period of time (usually around 10â€‰min) while carefully monitoring safety limits ( <a href="#R72">72</a> ).</p><p>åº”è¯¥ç»™å¤šå°‘æ¶²ä½“ä¸€ç›´äº‰è®ºæ¿€çƒˆã€‚è¯•å›¾é¢„å…ˆç¡®å®šéœ€è¦å¤šå°‘æ¶²ä½“åœ¨æ‰€æœ‰çš„ç—…äººäºšç¾¤ä¸­éƒ½æœªæˆåŠŸã€‚å› æ­¤ï¼Œæ¶²ä½“é‡çš„ç»™äºˆåº”è¯¥ç”±å¯¹æ¯ä¸ªæ‚£è€…è¿›è¡Œæ°å¦‚å…¶åˆ†çš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹æ¥æŒ‡å¯¼ã€‚å½“è¡€ç®¡å¼ åŠ›å®Œå¥½å­˜åœ¨æ—¶ï¼Œä»…ç›‘æµ‹åŠ¨è„‰è¡€å‹å¯èƒ½å°±è¶³å¤Ÿäº†ï¼Œä½†æ˜¯åœ¨è„“æ¯’ç—‡ä¼‘å…‹ï¼Œå¿ƒè¾“å‡ºé‡çš„å¢åŠ å¹…åº¦å¯èƒ½è¿œå¤§äºåŠ¨è„‰å‹ï¼ˆ70ï¼‰ï¼Œå› æ­¤ï¼Œéœ€è¦ç›‘æµ‹å¿ƒè¾“å‡ºé‡ã€‚è™½ç„¶ä½ CVP å¯ä»¥å¢åŠ è¡¥æ¶²çš„å¯ä¿¡åº¦ï¼Œä½†å•çº¯ CVP æµ‹é‡å€¼å¹¶ä¸æ˜¯éœ€è¦è¾“æ¶²çš„å¯é æŒ‡æ ‡ï¼ˆ71ï¼‰ã€‚åœ¨å¿«é€Ÿè¾“æ¶²è¿‡ç¨‹ä¸­ï¼ŒCVP çš„å˜åŒ–å¯¹æ¶²ä½“è€å—æ€§æä¾›äº†æ›´æœ‰ç”¨çš„ä¿¡æ¯ã€‚æ¶²ä½“çš„åˆ©ï¼ˆå¢åŠ å¿ƒè¾“å‡ºé‡ï¼‰ä¸å¼Šï¼ˆæ°´è‚¿çš„å½¢æˆï¼‰å¿«é€Ÿè¡¥æ¶²è¯•éªŒæŠ€æœ¯çš„åŸºç¡€ï¼Œåœ¨ç›¸å¯¹è¾ƒçŸ­çš„æ—¶é—´å†…ï¼ˆé€šå¸¸çº¦ 10 åˆ†é’Ÿï¼‰ç»™äºˆç›¸å¯¹å°‘é‡çš„æ¶²ä½“ï¼ˆé€šå¸¸çº¦ 200 æ¯«å‡ï¼‰ï¼ŒåŒæ—¶ä»”ç»†ç›‘æµ‹å®‰å…¨ç•Œé™ï¼ˆ72ï¼‰ã€‚</p><p>In patients treated with controlled mechanical ventilation, the effects of intermittent positive pressure ventilation on preload and stroke volume were proposed to detect fluid responsiveness. If mechanical ventilation induces respiratory variations in stroke volume (SVV) or in arterial pulse pressure (PPV), it is more likely that the patient is preload-dependent. During fluid administration, the decrease in PPV inversely correlates with the increase in cardiac output ( <a href="#R73">73</a> ). However, first introduced in the late 1990s, these dynamic measures of fluid responsiveness based on cardiopulmonary interactions have their limitations. PPV is only reliable in mechanically ventilated patients who are profoundly sedated (no spontaneous breathing) receiving a relatively large tidal volume, with modestly altered lung compliance, and no right ventricular failure, intra-abdominal hypertension, or severe arrhythmias. Conditions for its use are usually met during surgical interventions, where goal-directed fluid management strategies based on such indices (PPV or SVV) have been shown to reduce postoperative complications ( <a href="#R74">74</a> ); however, in the ICU, very few patients fulfill optimal conditions ( <a href="#R75">75</a> , <a href="#R76">76</a> ). Additional tests that rely on the dynamics of PPV have been proposed, including the positive end-expiratory pressure or the tidal volume challenge ( <a href="#R77">77</a> ).</p><p>åœ¨æ¥å—æ§åˆ¶æ€§æœºæ¢°é€šæ°”æ²»ç–—çš„æ‚£è€…ä¸­ï¼Œæœ‰äººæå‡ºç”¨é—´æ­‡æ€§æ­£å‹é€šæ°”å¯¹å‰è´Ÿè·å’Œæ¯æé‡çš„å½±å“åˆ¤æ–­æ¶²ä½“ååº”æ€§ã€‚å¦‚æœæœºæ¢°é€šæ°”å¼•èµ·éšå‘¼å¸çš„æ¯æé‡å˜å¼‚ï¼ˆSVVï¼‰æˆ–åŠ¨è„‰è„‰æå‹å˜å¼‚ï¼ˆPPVï¼‰ï¼Œé‚£ä¹ˆç—…äººå¾ˆæœ‰å¯èƒ½å­˜åœ¨å‰è´Ÿè·ä¾èµ–æ€§çš„ã€‚åœ¨è¾“æ¶²æœŸé—´ï¼ŒPPV çš„ä¸‹é™ä¸å¿ƒè¾“å‡ºé‡çš„å¢åŠ æˆåæ¯”ï¼ˆ73ï¼‰ã€‚ç„¶è€Œï¼Œè¿™äº›20 ä¸–çºª 90 å¹´ä»£æœ«é¦–æ¬¡å¼•å…¥çš„åŸºäºå¿ƒè‚ºäº¤äº’ä½œç”¨çš„æ¶²ä½“ååº”æ€§åŠ¨æ€æµ‹é‡æ–¹æ³•æœ‰å…¶å±€é™æ€§ã€‚PPV åªåœ¨æ·±åº¦é•‡é™ï¼ˆæ— è‡ªä¸»å‘¼å¸ï¼‰ï¼Œæ½®æ°”é‡ç›¸å¯¹è¾ƒå¤§ï¼Œè‚ºé¡ºåº”æ€§æ”¹å˜é€‚ä¸­ï¼Œæ²¡æœ‰å³å¿ƒå®¤è¡°ç«­ã€è…¹è…”å†…é«˜å‹æˆ–ä¸¥é‡å¿ƒå¾‹å¤±å¸¸çš„æœºæ¢°é€šæ°”çš„ç—…äººä¸­æ‰å¯é ã€‚åœ¨å¤–ç§‘æ‰‹æœ¯ä¸­é€šå¸¸æ»¡è¶³è¿™äº›åº”ç”¨æ¡ä»¶ï¼ŒåŸºäºæ­¤ç±»æŒ‡æ ‡ï¼ˆPPV æˆ– SVVï¼‰çš„ç›®æ ‡å¯¼å‘æ¶²ä½“ç®¡ç†ç­–ç•¥å·²è¢«è¯æ˜å¯ä»¥å‡å°‘æœ¯åå¹¶å‘ç—‡ï¼ˆ74ï¼‰ï¼›ç„¶è€Œï¼Œåœ¨ ICU ä¸­ï¼Œå¾ˆå°‘æœ‰ç—…äººè¾¾åˆ°æœ€ä½³æ¡ä»¶ï¼ˆ75,76ï¼‰ã€‚å·²ç»æå‡ºäº†åŸºäº PPV åŠ¨æ€å˜åŒ–çš„å…¶ä»–æµ‹è¯•æ–¹æ³•ï¼ŒåŒ…æ‹¬å‘¼æ°”æœ«æ­£å‹æˆ–æ½®æ°”é‡è´Ÿè·è¯•éªŒï¼ˆ77ï¼‰ã€‚</p><p>A passive leg raising test was proposed as an alternative method ( <a href="#R78">78</a> ), avoiding, in principle, the fluid bolus of a fluid challenge. However, there are two key limitations: one is that the test may represent a stimulus in the unsedated patient, resulting in an adrenergic response regardless of the fluid status; the other is that if there is a positive response (i.e., indicating fluid responsiveness), the increase in stroke volume is very transient, and appropriate monitoring must be used to ensure any change is identified reliably.</p><p>ä½œä¸ºæ›¿ä»£æœ‰äººæå‡ºè¢«åŠ¨æŠ¬è…¿è¯•éªŒï¼ˆ78ï¼‰ï¼ŒåŸåˆ™ä¸Šé¿å…äº†ä¸ºäº†å®¹é‡è´Ÿè·è¯•éªŒéœ€è¦å¿«é€Ÿè¡¥æ¶²ã€‚ç„¶è€Œï¼Œæœ‰ä¸¤ç‚¹é‡è¦é™åˆ¶ï¼šä¸€æ˜¯è¯¥è¯•éªŒå¯¹éé•‡é™çš„ç—…äººæ¥è¯´å¯èƒ½æ˜¯ä¸€ç§åˆºæ¿€ï¼Œå¯¼è‡´è‚¾ä¸Šè…ºç´ èƒ½ååº”ï¼Œè€Œä¸æ¶²ä½“çŠ¶æ€æ— å…³ï¼›äºŒæ˜¯å¦‚æœååº”ä¸ºé˜³æ€§ï¼ˆå³è¡¨æ˜æœ‰æ¶²ä½“ååº”æ€§ï¼‰ï¼Œæ­¤æ—¶æ¯æé‡çš„å¢åŠ æ˜¯éå¸¸çŸ­æš‚çš„ï¼Œå¿…é¡»é‡‡ç”¨é€‚å½“çš„ç›‘æµ‹ç¡®ä¿æ¯æé‡çš„ä»»ä½•å˜åŒ–éƒ½èƒ½å¯é åˆ†è¾¨ã€‚</p><h3 id="type-of-fluid-and-blood-transfusions-è¾“æ¶²å’Œè¾“è¡€çš„ç§ç±»ã€‚" tabindex="-1"><a class="header-anchor" href="#type-of-fluid-and-blood-transfusions-è¾“æ¶²å’Œè¾“è¡€çš„ç§ç±»ã€‚" aria-hidden="true">#</a> Type of Fluid and Blood Transfusions.è¾“æ¶²å’Œè¾“è¡€çš„ç§ç±»ã€‚</h3><p>A comprehensive discussion on the different effects of different colloids and crystalloids (albumin or hydroxyethyl starch, saline or balanced solutions) is beyond the scope of the present review, but fluid choices remain a highly controversial topic.</p><p>æœ¬æ–‡ä¸å¯¹å„ç§èƒ¶ä½“å’Œæ™¶ä½“æ¶²ï¼ˆç™½è›‹ç™½æˆ–ç¾Ÿä¹™åŸºæ·€ç²‰ã€ç”Ÿç†ç›æ°´æˆ–å¹³è¡¡ç›æ¶²ï¼‰çš„å„ç§æ•ˆæœè¿›è¡Œå…¨é¢è®¨è®ºï¼Œä½†æ¶²ä½“çš„é€‰æ‹©ä»ç„¶æ˜¯ä¸€ä¸ªæå…·äº‰è®®çš„è¯é¢˜ã€‚</p><p>Transfusion strategies have also evolved with time. When a patient should be transfused remains a matter of debate. There is no doubt that the maintenance of hemoglobin levels greater than 10â€‰g/dL resulted in excess transfusions, but the pendulum may have swung too far in the other direction following RCTs showing similar outcomes when transfusions are given only when hemoglobin falls less than 7â€‰g/dL ( <a href="#R57">57</a> ). A recent review of the available data indicated that blood transfusion may increase Vo<sub>2</sub> in critically ill patients ( <a href="#R79">79</a> ), and there is now broad consensus that the decision to transfuse should not be based on a hemoglobin level alone but also on other factors, including patient age, hemodynamic status, and cardiovascular comorbidity ( <a href="#R80">80</a> ). A reasonable approach today would be that blood transfusion can be safely withheld when the hemoglobin is above 9â€‰g/dL and should be given when hemoglobin is below 7â€‰g/dL; decisions to transfuse should be individualized when the hemoglobin is between these two values.</p><p>è¾“è¡€ç­–ç•¥åŒæ ·éšæ—¶é—´è€Œæ¼”å˜ã€‚ç—…äººä½•æ—¶åº”è¯¥è¾“è¡€ä»ç„¶æ˜¯ä¸€ä¸ªæœ‰äº‰è®®çš„é—®é¢˜ã€‚æ¯«æ— ç–‘é—®ï¼Œä¿æŒè¡€çº¢è›‹ç™½æ°´å¹³é«˜äº 10g/dL ä¼šå¯¼è‡´è¿‡é‡è¾“è¡€ï¼Œä½† RCT ç ”ç©¶æ˜¾ç¤ºè¡€çº¢è›‹ç™½ä½äº 7g/dL æ—¶æ‰è¾“è¡€é¢„åç›¸ä¼¼ï¼Œå¯¼è‡´çŸ«æ‰è¿‡æ­£ï¼ˆ57ï¼‰ã€‚å¯¹ç°æœ‰è¯æ®çš„æœ€æ–°ç»¼è¿°æ˜¾ç¤ºï¼Œè¾“è¡€å¯èƒ½ä¼šå¢åŠ å±é‡ç—…äººçš„ Vo<sub>2</sub>ï¼ˆ79ï¼‰ï¼Œç°åœ¨çš„å¹¿æ³›å…±è¯†è®¤ä¸ºï¼Œå†³å®šæ˜¯å¦è¾“è¡€ä¸è¦ä»…çœ‹è¡€çº¢è›‹ç™½æ°´å¹³ï¼Œè¿˜è¦è€ƒè™‘å…¶ä»–å› ç´ ï¼ŒåŒ…æ‹¬ç—…äººå¹´é¾„ã€è¡€æµåŠ¨åŠ›å­¦çŠ¶æ€å’Œå¿ƒè¡€ç®¡ç–¾ç—…ï¼ˆ80ï¼‰ã€‚ç›®å‰åˆç†çš„åšæ³•æ˜¯ï¼Œå½“è¡€çº¢è›‹ç™½é«˜äº 9g/dL æ—¶å¯ä»¥å®‰å…¨åœ°åœæ­¢è¾“è¡€ï¼Œå½“è¡€çº¢è›‹ç™½ä½äº 7g/dL æ—¶åº”è¾“è¡€ï¼›å½“è¡€çº¢è›‹ç™½åœ¨è¿™ä¸¤ä¸ªæ•°å€¼ä¹‹é—´æ—¶ï¼Œåº”æ ¹æ®ä¸ªä½“åŒ–å†³å®šæ˜¯å¦è¾“è¡€ã€‚</p><h3 id="pump-æ³µ" tabindex="-1"><a class="header-anchor" href="#pump-æ³µ" aria-hidden="true">#</a> Pump æ³µ</h3><p>Various vasopressor agents have been proposed, including norepinephrine, dopamine, phenylephrine, metaraminol, mephentermine, and others, but norepinephrine is now established as the initial vasopressor of choice ( <a href="#R81">81</a> ). Importantly, administration of vasopressors can decrease blood flow to nonvital organs, in particular to the kidneys. The pharmacology of dopamine was particularly appealing for its use as a vasopressor, because dopaminergic receptors are more numerous in the splanchnic and renal circulations. However, the administration of low-dose dopamine, although initially promoted by MacCannell et al ( <a href="#R82">82</a> ) in the 1960s, was later shown not to be associated with renal protective effects in patients with shock ( <a href="#R83">83</a> ). The use of dopamine has been shown to be associated with higher mortality rates than norepinephrine in shock states ( <a href="#R81">81</a> , <a href="#R84">84</a> ) and use of dopamine as a vasopressor has been largely abandoned.</p><p>æŒ‡å®šä½¿ç”¨çš„å„ç§å‡å‹è¯ç‰©ï¼ŒåŒ…æ‹¬å»ç”²è‚¾ä¸Šè…ºç´ ã€å¤šå·´èƒºã€è‹¯è‚¾ä¸Šè…ºç´ ã€é—´ç¾Ÿèƒºã€ç¾èŠ¬ä¸èƒºç­‰ï¼Œç›®å‰å·²ç¡®å®šå»ç”²è‚¾ä¸Šè…ºç´ ä¸ºåˆå§‹é¦–é€‰å‡å‹è¯ç‰©ï¼ˆ81ï¼‰ã€‚é‡è¦çš„æ˜¯ï¼Œç»™ä¸å‡å‹è¯ç‰©ä¼šå‡å°‘éç”Ÿå‘½å™¨å®˜çš„è¡€æµé‡ï¼Œç‰¹åˆ«æ˜¯è‚¾è„ã€‚å¤šå·´èƒºçš„è¯ç†ä½œç”¨ç‰¹åˆ«é€‚åˆæŠŠå®ƒç”¨ä½œå‡å‹è¯ï¼Œå› ä¸ºè„¾è‚¾å¾ªç¯ä¸­æœ‰å¤§é‡å¤šå·´èƒºèƒ½å—ä½“ã€‚ç„¶è€Œï¼Œå°½ç®¡æœ€åˆ MacCannell ç­‰äºº(82)åœ¨ 20 ä¸–çºª 60 å¹´ä»£æå€¡ä½¿ç”¨å°å‰‚é‡å¤šå·´èƒºï¼Œä½†åæ¥è¯æ˜åœ¨ä¼‘å…‹ç—…äººä¸­æ²¡æœ‰è‚¾è„ä¿æŠ¤ä½œç”¨ï¼ˆ83ï¼‰ã€‚åœ¨ä¼‘å…‹çŠ¶æ€ä¸‹ï¼Œä½¿ç”¨å¤šå·´èƒºçš„æ­»äº¡ç‡é«˜äºå»ç”²è‚¾ä¸Šè…ºç´ ï¼ˆ81,84ï¼‰ï¼Œå› æ­¤ä¸¥æ ¼æ¥è¯´å·²ç»æ”¾å¼ƒäº†æŠŠå¤šå·´èƒºç”¨ä½œå‡å‹è¯ã€‚</p><p>The place of other vasopressor agents remains undefined. The risk with these agents is a decrease in cardiac output. Vasopressin has been widely used without evidence of clinical benefit. Benefit may be found when vasopressin is administered early to prevent capillary leakage, but the risk is that it may decrease blood flow, especially in the hepatosplanchnic and the coronary circulations. Hence, close hemodynamic monitoring is required to ensure that cardiac output is well preserved ( <a href="#R85">85</a> ). Similarly, administration of selepressin, a vasopressin derivative, was not found to be beneficial in a study where cardiac output was not monitored ( <a href="#R86">86</a> ). Angiotensin II has been reintroduced as a vasopressor ( <a href="#R87">87</a> ), but its indications are not well defined.</p><p>å…¶ä»–ç¼©è¡€ç®¡è¯ç‰©çš„åœ°ä½ä»æœªæ˜ç¡®ã€‚è¿™äº›è¯ç‰©çš„é£é™©åœ¨äºé™ä½å¿ƒè¾“å‡ºé‡ã€‚è¡€ç®¡åŠ å‹ç´ å·²è¢«å¹¿æ³›ä½¿ç”¨ï¼Œä½†æ²¡æœ‰è¯æ®è¡¨æ˜å…¶å¯¹ä¸´åºŠæœ‰ç›Šã€‚å½“æ—©æœŸä½¿ç”¨è¡€ç®¡åŠ å‹ç´ ä»¥é˜²æ­¢æ¯›ç»†è¡€ç®¡æ¸—æ¼æ—¶ï¼Œå¯èƒ½ä¼šæœ‰å¥½å¤„ï¼Œä½†é£é™©æ˜¯å®ƒå¯èƒ½ä¼šå‡å°‘è¡€æµï¼Œç‰¹åˆ«æ˜¯å¯¹è‚è„¾å’Œå† çŠ¶åŠ¨è„‰å¾ªç¯ã€‚å› æ­¤ï¼Œéœ€è¦å¯†åˆ‡ç›‘æµ‹è¡€æµåŠ¨åŠ›å­¦ä»¥ç¡®ä¿å¿ƒè¾“å‡ºé‡ç»´æŒå¾—å¾ˆå¥½ï¼ˆ85ï¼‰ã€‚åŒæ ·ï¼Œåœ¨ä¸€é¡¹ç ”ç©¶ä¸­ï¼Œæœªç›‘æµ‹å¿ƒè¾“å‡ºé‡ï¼Œç»™äºˆ selepressin ï¼ˆä¸€ç§è¡€ç®¡åŠ å‹ç´ è¡ç”Ÿç‰©ï¼‰å¹¶æœªå‘ç°æœ‰ç›Šï¼ˆ86ï¼‰ã€‚è¡€ç®¡ç´§å¼ ç´  II å·²è¢«é‡æ–°ç”¨ä½œå‡å‹è¯ï¼ˆ87ï¼‰ï¼Œä½†å…¶é€‚åº”ç—‡å°šæœªæ˜ç¡®ç•Œå®šã€‚</p><p>Although in the past, vasopressor therapy was initiated only when it was considered that the patient was not responding to fluids, more recent studies have indicated that arterial hypotension should be avoided in all cases. Even transient hypotension can be associated with an increase in organ failure ( <a href="#R88">88</a> ) or mortality ( <a href="#R89">89</a> ) and early norepinephrine administration to restore arterial pressure seems to have beneficial effects on outcomes ( <a href="#R90">90</a> ). The optimal arterial pressure target in shock states has been a topic of intense investigation ( <a href="#R58">58</a> , <a href="#R91">91</a> ), but no globally acceptable ideal value has been identified because arterial pressure targets should be personalized taking into account various factors, including, among others, history of chronic hypertension, current disease process, and hemodynamic status ( <a href="#R92">92</a> ).</p><p>å°½ç®¡åœ¨è¿‡å»ï¼Œåªæœ‰åœ¨è®¤ä¸ºç—…äººå¯¹æ¶²ä½“æ²¡æœ‰ååº”æ—¶æ‰å¼€å§‹ä½¿ç”¨ç¼©è¡€ç®¡æ²»ç–—ï¼Œä½†æœ€è¿‘çš„ç ”ç©¶è¡¨æ˜ï¼Œä»»ä½•æƒ…å†µä¸‹éƒ½åº”é¿å…ä½è¡€å‹ã€‚å³ä½¿æ˜¯çŸ­æš‚çš„ä½è¡€å‹ä¹Ÿå¯èƒ½å¯¼è‡´å™¨å®˜è¡°ç«­ï¼ˆ88ï¼‰æˆ–æ­»äº¡ç‡ï¼ˆ89ï¼‰å¢åŠ ï¼Œå°½æ—©ç»™äºˆå»ç”²è‚¾ä¸Šè…ºç´ æ¢å¤è¡€å‹ä¼¼ä¹èƒ½æ”¹å–„é¢„åï¼ˆ90ï¼‰ã€‚ä¼‘å…‹çŠ¶æ€ä¸‹çš„æœ€ä½³è¡€å‹ç›®æ ‡ä¸€ç›´æ˜¯ä¸€ä¸ªæ·±å…¥ç ”ç©¶çš„è¯¾é¢˜ï¼ˆ58,91ï¼‰ï¼Œä½†æ˜¯éƒ½è®¤å¯çš„ç†æƒ³å€¼å°šæœªç¡®å®šï¼Œå› ä¸ºè¡€å‹ç›®æ ‡åº”è¯¥æ˜¯ä¸ªæ€§åŒ–çš„ï¼Œè¦è€ƒè™‘åˆ°å„ç§å› ç´ ï¼ŒåŒ…æ‹¬æ…¢æ€§é«˜è¡€å‹ç—…å²ã€å½“å‰ç–¾ç—…è¿‡ç¨‹å’Œè¡€æµåŠ¨åŠ›å­¦çŠ¶æ€ï¼ˆ92ï¼‰ã€‚</p><p>Dobutamine has been considered as the inotropic agent of choice in case of myocardial failure. Initially considered as inappropriate for use in septic shock, it has found a place when response to fluids is limited. Since optimization of hemodynamic variables is usually considered as standard of care, conduct of a large RCT to evaluate the potential benefit or harm of dobutamine would be difficult.</p><p>å¤šå·´é…šä¸èƒºè¢«è®¤ä¸ºæ˜¯å¿ƒè‚Œè¡°ç«­æ—¶ä½¿ç”¨çš„æ­£æ€§è‚ŒåŠ›è¯ç‰©ã€‚æœ€åˆè¢«è®¤ä¸ºä¸é€‚åˆç”¨äºè„“æ¯’ç—‡ä¼‘å…‹ï¼Œä½†å½“å¯¹æ¶²ä½“çš„ååº”æœ‰é™æ—¶ï¼Œå¤šå·´é…šä¸èƒºæ˜¯å¯ä»¥ä½¿ç”¨çš„ã€‚ç”±äºè¡€æµåŠ¨åŠ›å­¦å‚æ•°çš„ä¼˜åŒ–é€šå¸¸è¢«è®¤ä¸ºæ˜¯æ ‡å‡†æ²»ç–—ï¼Œå› æ­¤è¿›è¡Œå¤§è§„æ¨¡çš„ RCT ç ”ç©¶æ¥è¯„ä¼°å¤šå·´é…šä¸èƒºçš„æ½œåœ¨ç›Šå¤„æˆ–å±å®³æ˜¯å¾ˆå›°éš¾çš„ã€‚</p><p>Although their long half-life is not particularly desirable, phosphodiesterase inhibitors (like milrinone) and levosimendan can find a place in the management of cardiogenic shock, but their vasodilating effects have limited their place in the management of septic shock. There is no place for routine administration of any inotropic agent in these patients, even levosimendan ( <a href="#R93">93</a>) .</p><p>å°½ç®¡ç£·é…¸äºŒé…¯é…¶æŠ‘åˆ¶å‰‚ï¼ˆå¦‚ç±³åŠ›å†œï¼‰å’Œå·¦è¥¿å­Ÿæ—¦çš„é•¿åŠè¡°æœŸä¸æ˜¯ç‰¹åˆ«ç†æƒ³ï¼Œä½†åœ¨è„“æ¯’ç—‡ä¼‘å…‹ç®¡ç†ä¸­ä»æœ‰ä¸€å¸­ä¹‹åœ°ï¼Œä¸è¿‡å®ƒä»¬çš„è¡€ç®¡æ‰©å¼ ä½œç”¨é™åˆ¶äº†å…¶åœ¨è„“æ¯’ç—‡ä¼‘å…‹ç®¡ç†ä¸­çš„åœ°ä½ã€‚ä»»ä½•æ­£æ€§è‚ŒåŠ›è¯ç‰©åœ¨è¿™ç±»æ‚£è€…éƒ½ä¸ä½œä¸ºå¸¸è§„ä½¿ç”¨ï¼Œå³ä½¿æ˜¯å·¦è¥¿å­Ÿæ—¦ï¼ˆ93ï¼‰ã€‚</p><h3 id="the-future-of-hemodynamic-monitoring-è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹çš„æœªæ¥" tabindex="-1"><a class="header-anchor" href="#the-future-of-hemodynamic-monitoring-è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹çš„æœªæ¥" aria-hidden="true">#</a> The Future of Hemodynamic Monitoring è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹çš„æœªæ¥</h3><p>Medical and scientific technology continues to advance at an extraordinary pace, and this will continue to impact the field of hemodynamic monitoring in shock. New tiny, flexible noninvasive sensors that can be attached to the skin or items of clothing are already available and can provide continuous monitoring of multiple variables ( <a href="#R94">94</a> ). These values can be transmitted wirelessly to central computers or systems or to healthcare workersâ€™ smartphones or smartwatches. Artificial intelligence will increasingly be used to interpret such signals and suggest or even start appropriate therapy. There is already renewed interest in clinical automation with automated closed-loop control systems ( <a href="#R95">95</a> ). The integration of feedback control systems and artificial intelligence into medical device systems has the potential to improve adherence to prescribed treatment regimens and protocols, and enable rapid adaptation to new or changing therapeutic strategies. In the future, it is likely that personalized titration of drugs will be administered by automated systems using data previously gathered from patients with similar demographics and disease patterns. These systems would be able to more accurately predict the response of a given patient to specific drugs and use these predictive models within their treatment protocols, thus facilitating a personalized medicine approach. Echocardiography probes will also become even smaller and even more widely available and used. Although costs remain high at present, these will decrease as such tools become more widespread. However, further study needs to determine how best such innovations can be used in the critically ill to improve outcomes before they become a routine presence on our ICUs.</p><p>åŒ»å­¦å’Œç§‘å­¦æŠ€æœ¯ç»§ç»­ä»¥æƒŠäººçš„é€Ÿåº¦å‘å±•ï¼Œè¿™å°†ç»§ç»­å½±å“ä¼‘å…‹çš„è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹é¢†åŸŸã€‚æ–°çš„å¾®å°çš„ã€çµæ´»çš„æ— åˆ›ä¼ æ„Ÿå™¨å¯ä»¥é™„ç€åœ¨çš®è‚¤æˆ–è¡£æœä¸Šï¼Œå¹¶ä¸”å¯ä»¥å¯¹å¤šä¸ªå‚æ•°è¿›è¡Œè¿ç»­ç›‘æµ‹ï¼ˆ94ï¼‰ã€‚è¿™äº›æ•°å€¼å¯ä»¥æ— çº¿ä¼ è¾“åˆ°ä¸­å¤®ç”µè„‘æˆ–ç³»ç»Ÿï¼Œæˆ–ä¼ è¾“åˆ°åŒ»æŠ¤äººå‘˜çš„æ™ºèƒ½æ‰‹æœºæˆ–æ™ºèƒ½æ‰‹è¡¨ã€‚äººå·¥æ™ºèƒ½å°†è¶Šæ¥è¶Šå¤šåœ°è¢«ç”¨æ¥è§£é‡Šè¿™äº›ä¿¡å·ï¼Œç»™å‡ºå»ºè®®ç”šè‡³è‡ªåŠ¨å¼€å§‹è¿›è¡Œé€‚å½“çš„æ²»ç–—ã€‚äººä»¬å·²ç»å¯¹ä¸´åºŠè‡ªåŠ¨åŒ–ä¸è‡ªåŠ¨åŒ–é—­ç¯æ§åˆ¶ç³»ç»Ÿé‡æ–°åˆäº§ç”Ÿäº†å…´è¶£ï¼ˆ95ï¼‰ã€‚å°†åé¦ˆæ§åˆ¶ç³»ç»Ÿå’Œäººå·¥æ™ºèƒ½æ•´åˆåˆ°åŒ»ç–—è®¾å¤‡ç³»ç»Ÿä¸­ï¼Œæœ‰å¯èƒ½æ”¹å–„å¯¹åˆ¶å®šå¥½çš„æ²»ç–—æ–¹æ¡ˆå’Œæµç¨‹çš„ä¾ä»æ€§ï¼Œå¹¶èƒ½å¿«é€Ÿé€‚åº”æ–°çš„æ²»ç–—ç­–ç•¥æˆ–æ²»ç–—ç­–ç•¥çš„æ”¹å˜ã€‚åœ¨æœªæ¥ï¼Œæœ‰å¯èƒ½ç”±è‡ªåŠ¨åŒ–ç³»ç»Ÿåˆ©ç”¨å…ˆå‰ä»å…·æœ‰ç±»ä¼¼äººå£ç»Ÿè®¡å­¦å’Œç–¾ç—…æ¨¡å¼çš„ç—…äººèº«ä¸Šæ”¶é›†çš„æ•°æ®æ¥è¿›è¡Œè¯ç‰©çš„ä¸ªæ€§åŒ–æ»´å®šã€‚è¿™äº›ç³»ç»Ÿå°†èƒ½å¤Ÿæ›´å‡†ç¡®åœ°é¢„æµ‹ç‰¹å®šç—…äººå¯¹ç‰¹å®šè¯ç‰©çš„ååº”ï¼Œå¹¶åœ¨å…¶æ²»ç–—æ–¹æ¡ˆä¸­ä½¿ç”¨è¿™äº›é¢„æµ‹æ¨¡å‹ï¼Œä»è€Œä¿ƒè¿›ä¸ªæ€§åŒ–åŒ»ç–—æ–¹æ³•çš„å®æ–½ã€‚è¶…å£°å¿ƒåŠ¨å›¾æ¢å¤´ä¹Ÿå°†å˜å¾—æ›´å°ï¼Œç”šè‡³æ™®åŠæ›´å¹¿æ³›è€Œä¸”åº”ç”¨èŒƒå›´æ›´å¹¿ã€‚è™½ç„¶ç›®å‰çš„æˆæœ¬ä»ç„¶å¾ˆé«˜ï¼Œä½†éšç€è¿™äº›å·¥å…·çš„æ™®åŠï¼Œæˆæœ¬ä¼šé™ä½ã€‚ç„¶è€Œï¼Œåœ¨è¿™äº›å·¥å…·æˆä¸ºé‡ç—‡ç›‘æŠ¤å®¤çš„å¸¸è§„å·¥å…·ä¹‹å‰ï¼Œæˆ‘ä»¬è¿˜éœ€è¦è¿›ä¸€æ­¥ç ”ç©¶ï¼Œä»¥ç¡®å®šå¦‚ä½•åœ¨é‡ç—‡æ‚£è€…ä¸­æ›´å¥½åœ°ä½¿ç”¨è¿™äº›åˆ›æ–°å·¥å…·ï¼Œä»¥æ”¹å–„æ²»ç–—æ•ˆæœã€‚</p><h2 id="conclusions-ç»“è®º" tabindex="-1"><a class="header-anchor" href="#conclusions-ç»“è®º" aria-hidden="true">#</a> CONCLUSIONS ç»“è®º</h2><p>Hemodynamic monitoring and management have improved greatly in critical care and perioperative medicine over the past 50 years. Monitoring technology has evolved to enable very invasive devices to be replaced by much less invasive (and even totally noninvasive) equipmentâ€”even though we may lose some accuracy. Simultaneously, our whole approach to monitoring has shifted from using a few static, single measures to a functional, dynamic, and multivariable approach. Hemodynamic monitoring in the ICU needs to include more than simply blood pressure, heart rate, and urine output. Furthermore, any variable on its own provides relatively little information of a patientâ€™s hemodynamic status, particularly in the complex critically ill patient with shock. Rather the results from monitoring of several different variables need to be considered together to provide a complete hemodynamic picture for that particular patient at that moment in time ( <a href="#R15">15</a> ). The ability to monitor regional blood flow would be helpful but is not currently feasible clinically. We also have no ideal monitoring system for cell function, and monitoring of the microcirculation is still a work in progress. Yet, these areas could represent important targets for successful resuscitation in the future. Finally, we are moving from standard, protocolized hemodynamic strategies to a more personalized approach to ensure appropriate management of each patient according to his/her specific requirements during their disease trajectory ( <a href="#R92">92</a> ).</p><p>è¿‡å» 50 å¹´ï¼Œè¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹å’Œç®¡ç†åœ¨é‡ç—‡åŒ»å­¦å’Œå›´æœ¯æœŸåŒ»å­¦é¢†åŸŸçªé£çŒ›è¿›ã€‚ç›‘æµ‹æŠ€æœ¯çš„å‘å±•ä½¿ä¾µå…¥æ€§å¾ˆå¼ºçš„è®¾å¤‡è¢«å¾®åˆ›ï¼ˆç”šè‡³å®Œå…¨æ— åˆ›ï¼‰è®¾å¤‡æ‰€å–ä»£-å°½ç®¡å‡†ç¡®æ€§ç¨æœ‰ä¸‹é™ã€‚åŒæ—¶ï¼Œæˆ‘ä»¬çš„æ•´ä¸ªç›‘æµ‹æ–¹æ³•å·²ç»ä»ä½¿ç”¨å°‘æ•°é™æ€ã€å•ä¸€çš„æ–¹æ³•è½¬å˜ä¸ºåŠŸèƒ½æ€§çš„ã€åŠ¨æ€çš„å’Œå¤šå‚æ•°çš„æ–¹æ³•ã€‚ICU è¡€æµåŠ¨åŠ›å­¦ç›‘æµ‹éœ€è¦åŒ…æ‹¬æ›´å¤šå†…å®¹ï¼Œè€Œä¸ä»…ä»…æ˜¯è¡€å‹ã€å¿ƒç‡å’Œå°¿é‡ã€‚æ­¤å¤–ï¼Œä»»ä½•å‚æ•°æœ¬èº«æä¾›çš„ç—…äººè¡€æµåŠ¨åŠ›å­¦çŠ¶æ€çš„ä¿¡æ¯éƒ½ç›¸å¯¹è¾ƒå°‘ï¼Œç‰¹åˆ«æ˜¯å¯¹äºå¤æ‚çš„ä¼‘å…‹é‡ç—‡ç—…äººã€‚ç›¸åï¼Œéœ€è¦å°†å‡ ç§ä¸åŒå‚æ•°çš„ç›‘æµ‹ç»“æœä¸€èµ·è€ƒè™‘ï¼Œä»¥æä¾›è¯¥ç‰¹å®šç—…äººåœ¨é‚£ä¸€åˆ»çš„å®Œæ•´è¡€æµåŠ¨åŠ›å­¦æƒ…å†µï¼ˆ15ï¼‰ã€‚æœ‰èƒ½åŠ›ç›‘æµ‹å±€éƒ¨è¡€æµä¼šå¾ˆæœ‰ç”¨ï¼Œä½†ç›®å‰åœ¨ä¸´åºŠä¸Šè¿˜ä¸å¯è¡Œã€‚æˆ‘ä»¬ä¹Ÿæ²¡æœ‰ç†æƒ³çš„ç»†èƒåŠŸèƒ½ç›‘æµ‹ç³»ç»Ÿï¼Œå¯¹å¾®å¾ªç¯çš„ç›‘æµ‹ä»å¤„äºç ”ç©¶å½“ä¸­ã€‚ç„¶è€Œï¼Œè¿™äº›é¢†åŸŸå¯èƒ½æ˜¯æœªæ¥æˆåŠŸå¤è‹çš„é‡è¦ç›®æ ‡ã€‚æœ€åï¼Œæˆ‘ä»¬æ­£åœ¨ä»æ ‡å‡†çš„ã€æµç¨‹åŒ–çš„è¡€æµåŠ¨åŠ›å­¦ç­–ç•¥å‘æ›´åŠ ä¸ªä½“åŒ–çš„æ–¹æ³•è½¬å˜ï¼Œä»è€Œç¡®ä¿æ ¹æ®æ¯ä¸ªç—…äººç—…ç¨‹ä¸­çš„ç‰¹å®šè¦æ±‚å¯¹å…¶è¿›è¡Œé€‚å½“çš„ç®¡ç†ï¼ˆ92ï¼‰ã€‚</p></div><!----><footer class="page-meta"><div class="meta-item edit-link"><a href="https://github.com/seasideccm/ssccm/edit/main/docs/bloodflow/techniques of blood flow/Hemodynamic_Monitoring_and_Support.md" rel="noopener noreferrer" target="_blank" aria-label="ç¼–è¾‘æ­¤é¡µ" class="nav-link label"><!--[--><svg xmlns="http://www.w3.org/2000/svg" class="icon edit-icon" viewbox="0 0 1024 1024" fill="currentColor" aria-label="edit icon"><path d="M430.818 653.65a60.46 60.46 0 0 1-50.96-93.281l71.69-114.012 7.773-10.365L816.038 80.138A60.46 60.46 0 0 1 859.225 62a60.46 60.46 0 0 1 43.186 18.138l43.186 43.186a60.46 60.46 0 0 1 0 86.373L588.879 565.55l-8.637 8.637-117.466 68.234a60.46 60.46 0 0 1-31.958 11.229z"></path><path d="M728.802 962H252.891A190.883 190.883 0 0 1 62.008 771.98V296.934a190.883 190.883 0 0 1 190.883-192.61h267.754a60.46 60.46 0 0 1 0 120.92H252.891a69.962 69.962 0 0 0-69.098 69.099V771.98a69.962 69.962 0 0 0 69.098 69.098h475.911A69.962 69.962 0 0 0 797.9 771.98V503.363a60.46 60.46 0 1 1 120.922 0V771.98A190.883 190.883 0 0 1 728.802 962z"></path></svg><!--]-->ç¼–è¾‘æ­¤é¡µ<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewbox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span><!----></a></div><!----><!----></footer><!----><!----><!----><!--]--></main><!--]--><footer class="footer-wrapper"><div class="footer">SSCC since 2021</div><div class="copyright">Copyright Â© 2022 SSCC</div></footer><!--]--></div><!--]--><!----><!--]--></div>
    <script type="module" src="/assets/app.c13ece5a.js" defer></script>
  </body>
</html>
